The Role of Histone Chaperone FACT Complex in Base Excision Repair Pathway and Its Therapeutic Potential in Colon Cancer and Medulloblastoma by Song, Heyu
University of Nebraska Medical Center 
DigitalCommons@UNMC 
Theses & Dissertations Graduate Studies 
Fall 12-20-2019 
The Role of Histone Chaperone FACT Complex in Base Excision 
Repair Pathway and Its Therapeutic Potential in Colon Cancer and 
Medulloblastoma 
Heyu Song 
University of Nebraska Medical Center 
Follow this and additional works at: https://digitalcommons.unmc.edu/etd 
 Part of the Cancer Biology Commons, Genetics Commons, Neoplasms Commons, and the 
Translational Medical Research Commons 
Recommended Citation 
Song, Heyu, "The Role of Histone Chaperone FACT Complex in Base Excision Repair Pathway and Its 
Therapeutic Potential in Colon Cancer and Medulloblastoma" (2019). Theses & Dissertations. 400. 
https://digitalcommons.unmc.edu/etd/400 
This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It 
has been accepted for inclusion in Theses & Dissertations by an authorized administrator of 
DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu. 
i 
 
THE ROLE OF HISTONE CHAPERONE FACT COMPLEX IN BASE 
EXCISION REPAIR PATHWAY AND ITS THERAPEUTIC 






Presented to the Faculty of 
the University of Nebraska Graduate College 
in Partial Fulfillment of the Requirements 
for the Degree of Doctor of Philosophy 
 
 
Medical Sciences Interdepartmental Area 
Graduate Program 
(Genetics, Cell Biology & Anatomy) 
 
Under the Supervision of Dr. Kishor K. Bhakat 
 
 







Kishor K. Bhakat, Ph.D.                     Laura D. Bilek, Ph.D. 
       Karen A. Gould, Ph.D.                       Tadayoshi Bessho, Ph.D.   
 




I would like to extend my gratitude to many people who have generously 
contributed to my time during graduate school.  
First, I would like to express my deepest appreciation to my mentor, Dr. Bhakat, 
who has been incredibly patient and supportive since the first day I joined the lab. Your 
logical and critical thinking has guided me through the graduate study and made such a 
comprehensive research project feasible. Thank you for your profound belief in my abilities 
and allowing me to grow. Your brilliant suggestions on both academic and personal levels 
have benefited me tremendously. 
I would also like to extend my sincere thanks to my committee members, Drs. 
Laura Bilek, Karen Gould and Tadayoshi Bessho, for their great support, constructive 
criticism and invaluable advice. I also wish to thank Dr. Gould and Dr. Bilek for their 
encouragement and patience throughout the duration of my graduate study. I very much 
appreciate Dr. Vimla Band for the unwavering support. Special thanks to Dr. Jenny Wang 
and her lab members for the great amount of assistance. I’d like to extend my gratitude 
for Dr. Sutapa Ray for the invaluable support and advice on the MB project. I’d also like to 
recognize the effort that I received from Dr. Shaoyan Xi from Sun Yat-sen University 
Cancer Center for our collaborative project. Many thanks to Dr. Kai Fu for his tremendous 
amount of help and support during this time. Thanks should also go to Dr. Hollingsworth 
for his critical reading and valuable comments for my manuscripts.  
I had great pleasure of working with my lab members, Somsubhra, Dan, Shrabasti, 
Pranjal, Suravi, Hannah and Mason. I’d like to acknowledge the assistance from Lynne, 
Bryan and Bhopal. I’d also like to recognize the help that I received from Jiang Jiang and 
Lijun at Tissue Science Facility, Salma Elhag at Tissue Bank, Grace and Kris from 
ii 
 
Comparative Medicine. Thanks are also due to the UNMC Graduate Studies Research 
Fellowships for the financial support that I otherwise would not have been able to develop 
my scientific discoveries. 
Finally, but by no means least, thanks go to mum, dad and my husband Jiping for 
almost unbelievable support. They are the most important people in my world and I 




THE ROLE OF HISTONE CHAPERONE FACT COMPLEX IN BASE 
EXCISION REPAIR PATHWAY AND ITS THERAPEUTIC 
POTENTIAL IN COLON CANCER AND MEDULLOBLASTOMA 
Heyu Song 
Supervisor: Kishor K. Bhakat, Ph.D. 
University of Nebraska Medical Center, 2019 
 
Base excision repair (BER) pathway is required for the removal of damaged bases 
caused by alkylation, oxidation and ring-saturation. Human apurinic/apyrimidinic 
endonuclease 1 (APE1) plays a central role in BER pathway. Although repair of damaged 
bases by recombinant APE1 has been well investigated in vitro, how APE1 gains access 
to damaged bases in the context of chromatin is largely unknown. A prominent member 
of the histone chaperone family, FACT (Facilitates Chromatin Transcription) is thought to 
reorganize nucleosomes through the destabilization of multiple intra-nucleosome contacts. 
FACT complex is composed of two polypeptides identified as SPT16 (Suppressor of Ty 
16) and SSRP1 (structure-specific recognition protein 1) that are both essential for 
nucleosome reorganization. Previous reports demonstrate that SPT16 is essential for 
transcription-coupled nucleotide excision repair (TC-NER) and homologous 
recombination repair (HRR). However, whether FACT complex interacts with APE1 and is 
involved in BER pathway remains unknown. 
Here, we identified both subunits (SPT16 & SSRP1) of FACT complex as the 
prominent interacting partners of APE1. We show that the interaction of APE1 with FACT 
complex enhances upon induction of DNA damages. We demonstrate that FACT complex 
not only promotes the binding and subsequent acetylation of APE1 (AcAPE1), but also 
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regulates the mobility and binding dynamics of APE1 to damage sites in chromatin. 
Furthermore, we found that FACT complex was required for efficient repair of DNA 
damages in BER pathway. 
Given the prognostic significance of APE1 overexpression in various cancers, we 
test the translational potential of targeting FACT complex to interfere BER function in two 
tumor models, colon cancer and medulloblastoma, a most common brain tumor in children.  
We show that both APE1 and FACT levels are elevated in primary tumor tissue of colon 
cancer and medulloblastoma patients. A group of small molecules currently in phase II 
clinical trial, curaxins, is found to cause chromatin trapping effect of FACT complex. We 
demonstrate that curaxins inhibit FACT function and exhibits synergistic effect of tumor 
killing when combined with chemotherapeutic agent both in vitro and in vivo using 
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Base excision repair pathway 
Human genome is continuously exposed to genotoxic stress. The maintenance of 
genome stability is critical for cell survival. Various forms of endogenous DNA damage are 
generated spontaneously everyday. With one exception, all the DNA repair pathways 
follow five steps: Recognition of damage by repair proteins, Removal, Reconstruction, and 
Reinstatement (3). Direct reversal, being the only exception, is the only single-step DNA 
repair process that removes an alkyl group from certain oxygen positions of damaged 
guanine and thymine bases without excising bases or distorting DNA’s phosphodiester 
backbone. Base modification is the most common lesion in DNA. Base excision repair 
(BER) pathway is responsible for repairing most of the endogenous DNA damage 
including alkylation, oxidation, deamination and depurination, as well as single-strand 
breaks (SSBs) (4). These small lesions do not distort the DNA helix structure, however, 
can change the base-pairing property of the genetic materials and thus are mutagenic and 
potentially carcinogenic if left unrepaired. Mismatch repair (MMR) corrects single-base 
mismatches (A:G, T:C) and misaligned short nucleotide repeats to ensure replication 
fidelity. Helix-distorting, bulky lesions and large adducts when only one of the two DNA 
strands is affected are repaired by Nucleotide excision repair (NER). On the other hand, 
double strand breaks (DSBs) are very toxic and hard to repair. Two main pathways are 
involved: nonhomologous end joining (NHEJ) and homologous recombination repair 
(HRR). 




i) Removal of DNA lesions by DNA glycosylase. The initial step of BER is 
excision of substrate base from duplex DNA by a DNA glycosylase. There are 
11 human glycosylases that recognizes non-functional bases and remove the 
damaged base by cleaving the N-glycosyl bond between the base and the 
sugar. This will result in either abasic sites or 3’-α β unsatuarted aldehyde and 
a 5’- phosphate. 
ii) Cleavage of abasic sites by apurinic/apyrimidinic (AP) endonuclease (APE). 
APE incises the DNA backbone immediately 5’ to the abasic site to generate a 
strand break with a priming 3’-OH group and a non-conventional 5’-
deoxyribose phosphate (dRP). APE1 exhibits 3'-phosphodiesterase, 3'-5'-
exonuclease, and 3'-phosphatase activities. The major AP endonuclease in 
mammals is APE1, which accounts for more than 95% of the total cellular AP 
site incision activity (5). The APE1 is essential for survival as previous study 
has shown that homozygous mutant mice lacking APEX gene die during 
embryonic development (6,7).  
iii) Removal of sugar remnant. The DNA strand breaks generated in the above 
process contain terminal blocking groups, such as 5’-dRP, 5’-OH, 3’-PO4, 3’-
phosphoglycolate (3’-PG), and 3’-PUA. These groups will block the 
downstream repair and must be removed. Various proteins are involved. For 
example, DNA polymerase β (Polβ) possesses a polymerase activity and a 
dRP lyase activity that is able to remove 5’-dRP (8). APE1 has 3’-
phosphodiesterase activity that can remove 3’-PG residues (9).  
iv) Single nucleotide gap filling by DNA polymerase. Polβ is the main human DNA 
polymerase that operates on short nucleotide gaps, such as those that arise 
during short-patch BER (SP-BER). It contains a 31-kDa polymerase domain 
and an amino-terminal 8-kDa lyase domain (10). A ‘‘knockout’’ of the polβ gene 
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in mice results in embryonic lethality, indicating its essential role during fetal 
development (11).  
v) Nick sealing by DNA ligase. In BER, this step is completed predominantly by 
DNA ligase I. Alternatively, DNA ligase III in complex with XRCC1 protein 
ligates the ends of the DNA strand. Both ligases are ATP-dependent and 
generate a covalent phosphodiester bond between the 3’-OH end of the 
upstream nucleotide and the 5’-PO4 end of the downstream nucleotide to seal 






Figure 1. Steps of BER pathway.  
Modified from Meas et al. (1). BER takes place by short-patch repair or long-patch repair 
that largely use different proteins downstream of the base excision. The repair process 
initiates with recognition and removal of damaged or inappropriate bases by DNA 
glycosylases, forming an AP site. These sites are cleaved by AP endonucleases, resulting 
in single-stranded breaks (SSBs). SSBs are processed by either “short-patch” (single 
nucleotide) or “long-patch” (2–10 new nucleotides) repair. Polβ is the main polymerase 




APE1 and its biochemical activities 
In 1990s, the transcript encoding the human AP endonuclease (at the time, termed 
APE, HAP1, and APEX, since named apurinic/apyrimidinic endonuclease 1 
[APE1]/APEX1) was cloned by the Demple, Hickson, and Seki groups (13-15). Around the 
same time, APE1 was independently identified (and the gene subsequently cloned) by 
Curran and colleagues as the major nuclear protein (termed REF-1) to stimulate the DNA-
binding activity of the AP-1 (Fos/Jun) transcription factor complex (16). Since then, APE1 
has been described as a multifunctional protein that contains several domains and 
participates in several biological processes (Figure 2).  
APE1 is a 36.5 kilodalton (kDa) protein encoded by a 3 kilobase (kb) gene, which 
is located on chromosome 14. It is expressed ubiquitously in humans, and depending on 
the cell types its concentration varies, average concentration of approximately 0.35 to 7 × 
106 molecules per cell. The biochemical activities of APE1 are summarized as follows. 
AP endonuclease activity. There are two types of AP endonuclease in human, 
including APE1 and APE2. With its robust activity, APE1 accounts for >95% of 
endonuclease function in cells (17). It plays a central role in BER by incising the DNA 5′ 
to AP sites to generate accessible 3′-OH termini prior to repair synthesis. APE1 uses a 
rigid, pre-formed, positively charged surface to kink the DNA helix and engulf the AP-DNA 
strand. APE1 inserts loops into both the DNA major and minor grooves and binds a flipped-
out AP site in a pocket that excludes DNA bases and racemized β-anomer AP sites (18). 
3′-repair diesterase. Early research shows that APE1 has not only a powerful 
class II AP site incision activity, but also the ability to excise 3′-end blocking groups. These 
3’-end damages include 3′-phosphates, 3′-phosphoglycolate esters, and 3′-deoxyribose 
fragments which are believed to prevent primer extension by a DNA polymerase or nick 
ligation by a DNA ligase (14,19). APE1 is rate limiting for the repair of DNA strand breaks 
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induced by hydrogen peroxide (presumably 3′-phosphates) and bleomycin (3′-
phosphoglycolates) (20). 
3′ to 5′ exonuclease. APE1 has 3′ to 5′ exonuclease activity. However, it is poorly 
processive and ≥100-fold less efficient than its AP endonuclease activity (15,21).  
RNA cleavage. APE1 exhibits RNase H activity. Similar to 3′ to 5′ exonuclease 
activity, the biological significance of this activity is unknown. Recently APE1 has been 
shown to be involved in RNA quality control as it has the ability to cleave AP sites in RNA 
to prevent error-prone translation (22,23). 
Nucleotide incision repair (NIR). In NIR, an endonuclease directly nicks DNA 
containing free radical-induced base lesions acting as a back-up repair pathway to BER 
(24). This endonuclease was identified to be APE1 in human (25). APE1 incises DNA 
containing 5,6-dihydro-2'-deoxyuridine, 5,6-dihydrothymidine, 5-hydroxy-2'-deoxyuridine, 
alpha-2'-deoxyadenosine and alpha-thymidine adducts, generating 3'-hydroxyl and 5'-
phosphate termini (25).  
Redox regulation. APE1 has been reported to modulate the redox status of both 
ubiquitous (e.g., AP-1, Egr-1, NF-κB, p53, CREB, and HIF-1α) and tissue-specific 
transcription factors (e.g., PEBP-2, Pax-5, and -8, TTF-1) with functions in stress 
responses and other cellular processes (26). 
Trans-acting modulation. APE1 is part of the components of negative Ca2+ 
responsive elements (nCaREs) that responds to a rising extracellular calcium level (27). 
This complex suppresses not only secretion of parathyroid hormone (PTH) but also 
expression of the PTH gene to ensure constant plasma Ca2+ level. APE1 binds to nCaRE 
PTH sequences in cooperation with the two subunits of the Ku antigen, p70 and p80 (28). 





Figure 2. Domain structure, amino acid sequence and posttranslational 
modifications of APE1.  
Adapted from Li M et al. Antioxid Redox Signal. 2014 (2). The nuclear localization 
sequence is localized in the N-terminal, spanning residues 1 to 34. The truncated form of 
NLS is called NΔ33. The endonuclease domain spans roughly from residues 64 to 318. 
Post-translational modifications including acetylation, phosphorylation and ubiquitination 
are depicted. NLS, nuclear localization signal; NES, nuclear export signal; MTS, 




Posttranslational modification of APE1 
 After translation, APE1 undergoes various modifications which in turn affect its 
endonuclease activity, redox function, transcriptional modulation and subcellular 
localization. So far four different types of PTMs (Figure 2) have been reported (reviewed 
in (30)). 
 Phosphorylation. APE1 could be phosphorylated with predicted sites at a.a. 
residues of 19T, 123S, or 233T by casein kinase II, which was reported to be enhancing 
its endonuclease activity (31). Later, Fritz et al. reported that phosphorylation enhanced 
Ref-1 activity but did not affect its nuclease activity (32).  The various results reported 
have not reached conclusion regarding the biological effect of APE1 phosphorylation. 
Additionally, APE1 phosphorylation activity in cells is very weak and endogenous 
phosphorylated APE1 has not been confirmed (33). 
 S-nitrosation. Qu et al. reported that nuclear-cytoplasmic translocation was 
dependent on S-nitrosation modification of APE1, as simultaneous mutation of S-
nitrosation target sites Cys93 and Cys310 completely abrogated the cytoplasmic 
redistribution. The modification in cells is induced by S-nitrosoglutathione, a nitric oxide 
donor and also an S-nitrosating agent (34). 
 Acetylation. Bhakat et al. reported in 2003 that the acetylation of APE1 was 
carried out by histone acetyl transferase (HAT) p300. The acetyl acceptor Lys residues 
were also found at K6 and K7 in the APE1 polypeptide (29). Later, the same group 
developed an antibody specifically directed at acetylated APE1 (AcAPE1), confirming the 
endogenous presence of AcAPE1 (35). Later, other Lys residues including K24, K25, K27, 
K31 and K32 were identified in the N-terminal domain (36,37). APE1 acetylation is a key 
modulation for its gene repressor function and in transcriptional activation of the multi-drug 
resistance gene MDR1. Recent report demonstrates that APE1 is acetylated (AcAPE1) 
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after binding to the AP sites in chromatin and that AcAPE1 is exclusively present on 
chromatin throughout the cell cycle. Acetylation-mediated neutralization of the positive 
charges of the lysine residues in the N-terminal domain of APE1 induces a conformational 
change; this in turn enhances the AP endonuclease activity of APE1 (38). 
 Ubiquitination. APE1 ubiquitination occurred specifically at Lys residues near the 
N-terminus, and was markedly enhanced by mouse double minute 2 (MDM2), the major 
intracellular p53 inhibitor. DNA damage agents increased APE1 ubiquitination. 
Interestingly, unlike the wild-type APE1, ubiquitin-APE1 fusion proteins were 
predominantly present in the cytoplasm (39). Further study revealed that 
monoubiquitinated APE1 was present in the nucleus, and analyzing global gene 
expression profiles with or without induction of a ubiquitin-APE1 fusion gene suggested 
that monoubiquitination enhanced the gene suppression activity of APE1 (40). 
 
Role of APE1 in tumors 
 The multifunctional nature of APE1 alludes to its expansive role in various diseases, 
especially cancers. APE1 is involved in processes such as tumorigenesis, cancer 
aggressiveness, increased angiogenesis, radiotherapeutic and chemotherapeutic 
resistance, and overall poor prognosis (reviewed in (41)). For example, APE1 has been 
studied in prostate cancer, where it demonstrates a higher percentage of cells staining 
positive for APE1 in the cytoplasm and an increased intensity of APE1 nuclear staining 
(42). Colon cancer, the second leading cause of cancer related death in the US, exhibits 
overexpression of APE1 (43). Similarly, APE1 overexpression has been observed in 
pancreatic cancer, ovarian cancer, breast cancer, non-small cell lung carcinoma, and 
medulloblastoma (44,45).  
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 APE1 possess two major functions in cells, including the critical role in BER 
pathway and transcriptional regulatory functions with redox and direct coactivator or 
corepressor functions. The finding of APE1 upregulation has led to the investigation of the 
role of APE1 in cancer. In colon cancer cells, using siRNA to knockdown APE1 has 
resulted in increased sensitivity to radiation therapy. This finding is further tested in 
xenograft model, where siRNA delivered subcutaneously leads to reduced tumor growth 
(46). Targeting Ref-1 function of APE1 via APX3330 inhibits the proliferation and adhesion 
of pancreatic cancer cell lines, arrests cell cycle progression, and decreases the 
transcriptional activation of major transcription factors (47,48). These findings have 
suggested that APE1 may be a target for cancer treatment, and has led to the search for 
APE1 inhibitors, which we will detail below. 
 
APE1 inhibitors 
APE1 appears to be a promising target for cancer therapy for the following reasons: 
1) The expression of APE1 is upregulated or dysregulated in multiple cancers. It has 
been shown to be elevated in NSCLC, breast cancer, osteosarcoma, melanoma, 
cervical cancer, bladder cancer, hepatocellular carcinoma, ovarian cancer, and 
colon cancer (reviewed in (45)).  
2) Interference or inhibition of APE1 function increases cytotoxicity of common 
chemotherapeutic agents, including temozolomide (TMZ), cisplatin, and 
gemcitabine.  
3) The overexpression of APE1 is correlated with poor prognostic features of cancer 
patients, such as chemoresistance, poor treatment response, poor survival and 




APE1 inhibitors have been under development over the past decades. Currently, there 
are two classes of inhibitors available, including methoxyamine (MX) and E3330. They 
have distinct mechanism of action and have been investigated extensively in prior 
literature. MX is an orally available agent that binds to the aldehyde on the AP site 
covalently and prevents APE1 from binding to damage sites (49). It is considered as 
indirect inhibitor of APE1, or more appropriately, inhibitor of BER pathway. It has also been 
used for AP site quantification (50). As a result, it lacks binding specificity and may causes 
off-target effects. For example, it will bind to any aldehyde group in DNA. Nevertheless, it 
has been introduced clinically in phase I trial as a component of combination therapy with 
fludarabine for advanced hematologic malignancies (51). It is used in 20 patients and 
hematologic toxicity was frequent; most common grade 3–4 toxicities were lymphopenia 
(70%), neutropenia (60%), leukopenia (50%) and anemia (40%). In another phase I trial, 
MX is combined with TMZ in patients with solid tumors and lymphomas (52,53). Similarly, 
hematologic toxicity was noted included neutropenia, anemia, thrombocytopenia, and 
hemolysis. It is deemed that MX is overall well tolerated in these studies. There are 
currently three phase II trial with one of them being terminated. In an effort to use MX 
combined with temozolomide in recurrent glioblastoma, the study was terminated because 
pre-specified response criteria are not met to proceed to next stage of study 
(NCT02395692). The other two studies are in active recruiting phase, including 
NCT02535312 that uses MX with cisplatin and pemetrexed disodium in advanced solid 
tumors or mesothelioma, and NCT01851369 that uses MX with temozolomide for relapsed 
solid tumors and lymphomas. 
As described previously, the redox domain of APE1 (often referred to as redox factor-
1, Ref-1) is involved in the activation of re-dox-sensitive transcription factors. E3330, a 
novel quinone derivative, was initially found to selectively inhibited NF-kappa B-mediated 
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gene expression without affecting degradation of I kappa B alpha, translocation of NF-
kappa B into the nucleus, or post-translational modification of NF-kappa B (54). Later, 
Shimizu et al used novel latex beads for rapid identification of drug receptors using affinity 
purification. E3330 was found to selectively inhibit the redox domain of APE1 (55). E3330 
exposure affects a number of critical intracellular pathways involved in endothelial cell 
differentiation, homeostasis and development, with the effect of inhibiting the in vitro 
growth of endothelial cell and endothelial progenitor cells (EPCs). The cytotoxicity of the 
combination of TNF-related apoptosis-inducing ligand, TNF alpha, Fas ligand, and E3330 
increased synergistically in a dose-dependent manner compared to either E3330 alone in 
all HCC cell lines by MTT assay. However, the combination of some chemotherapeutic 
drugs and E3330 did not decrease the cell viability (56). 
To sum up, biochemical, preclinical and clinical studies discussed in the previous 
section confirm that APE1 is a valid anticancer drug target. Currently there is no ideal 
inhibitor that inhibits APE1 DNA repair activity and augment cytotoxicity when combined 
with chemotherapeutic agents.  
 
Facilitates Chromatin Transcription (FACT) Complex 
Although repair of damaged bases by recombinant BER proteins has been well 
investigated in vitro, how repair factors gain access to damaged bases in the context of 
chromatin is largely unknown. The fundamental unit of the chromatin polymer is the 
nucleosome, which represents the first order of DNA packaging in the nucleus and as 
such is the principal structure that determines DNA accessibility. Histone chaperones are 
a diverse family of histone-binding proteins that shield non-specific interactions between 
the negatively charged DNA and the positively charged histones, to allow the ordered 
formation of the nucleosome structure. Other than having the common feature of being 
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acidic, histone chaperones are a diverse group of proteins with little sequence similarity. 
Histone chaperones sequester core histones from DNA until a more energetically 
favorable nucleosomal arrangement becomes available (57).  
The human FACT complex was first identified in 1998 as a factor essential for 
transcriptional elongation through chromatin (58). Later it was further characterized to be 
composed of two subunits, SSRP1 and SPT16, both of which are essential for its function. 
FACT complex has been previously shown to reorganize nucleosomes through the 
disruption of core histone-histone and histone-DNA interactions (59). It is also capable of 
depositing the H2A-H2B dimer and (H3-H4)2 tetramer onto DNA (60). Additionally, it has 
been linked to activation of the tumor suppressor protein p53 and to histone variant 
(H2AX-H2B) exchange in response to induced DNA damage (61,62). FACT is implicated 
in various chromatin processes including transcription and DNA replication, recombination, 
and repair (63), during which it functions by reorganizing nucleosomes through the 
disruption of core histone-histone and histone-DNA interactions. By promoting 
accelerated histone exchange, SPT16 is essential in the completion of transcription-
coupled nucleotide excision repair (TC-NER), allowing efficient restart of transcription after 
repair of the blocking lesions (64). In DNA double-strand break repair, SPT16 helps E3 
ubiquitin ligase RNF20 with the regulation of chromatin structure through ubiquitylation of 
histone H2B, so that early homologous recombination repair (HRR) proteins can access 
the DNA in eukaryotes during repair. Depletion of SPT16 causes pronounced defects in 
accumulations of repair proteins and, consequently, decreased HRR activity (65). 
While its involvement in nucleotide excision repair (NER) and double-strand break 
(DSB) repair pathway has been well demonstrated, whether FACT complex is involved in 





Curaxins is a group of small molecules that were identified in a phenotype-based 
screening for the ability to simultaneously activate p53 and inhibit NF-κB without causing 
detectable genotoxicity (66). In search for its mechanism of action, it was discovered that 
curaxins bind DNA via intercalation of the carbazole body accompanied by the protrusion 
of two side chains into the major groove and a third side chain into the minor groove of 
DNA, inducing tight binding of FACT to chromatin that results in functional inhibition (67). 
Later, Safina et al reports that binding of curaxins leads to uncoiling of nucleosomal DNA, 
accumulation of negative supercoiling and conversion of multiple regions of genomic DNA 
into left-handed Z-form. Nucleosome disassembly caused by curaxins opens multiple 
FACT-binding sites, which are normally hidden inside the nucleosome. The isolated C-
terminal intrinsically disordered domain (CID) of SSRP1, but not HMG domain, binds these 
alternative DNA structures and triggers p53 response (68). 
Curaxins have caught increasing attentions since the initiation of clinical trial. The 
first clinical phase I trial was launched in July 2013 to determine the maximally tolerated 
dose and recommended phase II dose of CBL0137 when administered intravenously (IV) 
to patients with metastatic or unresectable advanced solid malignancies (NCT01905228). 
Since then, two clinical trials with broader application were started for those with 
hematological malignancies, metastatic extremity melanoma or sarcoma (NCT02931110 
and NCT03727789).  
 
Hypothesis 
 Altered DNA repair processes have been observed in tumorigenesis and 
chemotherapy resistance, leading to tumor recurrence and eventually death. Alkylating 
agents remain a mainstay of chemotherapy. Consequently, it is necessary to elucidate the 
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mechanism underlying resistance to these agents before identifying an appropriate target 
for increasing chemosensitization. BER pathway is primarily involved in repairing both 
endogenous and exogenous genome damages induced by alkylating agents. APE1 plays 
a key role in the BER pathway via repairing AP sites generated spontaneously or after 
removal of alkylated bases by DNA glycosylases. Although repair of damaged bases by 
recombinant BER proteins has been well investigated in vitro, how repair factors gain 
access to damaged bases in the context of chromatin is largely unknown. Previously 
FACT complex has been shown to be involved in NER and DSB repair pathways. 
Nevertheless, the role of FACT in BER remains unclear. 
Our study shows that FACT is the prominent interacting partner of acetylated APE1 
(AcAPE1). Furthermore, we have shown that downregulation of FACT sensitizes tumor 
cells to alkylating drugs. We hypothesize that FACT is the key factor facilitating APE1 to 
access damage sites in chromatin and that this interaction is essential for efficient DNA 
damages repair and inducing chemoresistance in tumor cells (Figure 3). 
As corollary, we hypothesize that targeting the interaction of APE1 with FACT may 





Figure 3. Schematic depiction of our hypothesis.  
Eukaryotic genomes are highly condensed in chromatin, which is dominated by 
arrays of the basic repeating units termed nucleosome. This packaging limits the 
accessibility of DNA, thus creating a barrier that plays a major role in regulating 
nuclear processes such as DNA transcription, replication, and repair. In the setting 
of DNA damage, FACT complex creates a transiently accessible nucleosome 
structure to allow APE1 access to damage sites. Curaxins is a group of small 
molecules that causes chromatin trapping effect. We hypothesize that inhibition of 
FACT complex disrupts the interaction of FACT and APE1 and leads to 




CHAPTER 1. TARGETING HISTONE CHAPERONE FACT COMPLEX OVERCOMES 
5-FU RESISTANCE IN COLON CANCER 
 
Introduction  
Colorectal cancer (CRC) is the second leading cause of cancer related deaths in 
the US. According to the American Cancer Society, more than 50% of new cases are 
diagnosed at advanced stages and require adjuvant chemotherapy. The pyrimidine 
analog 5-fluorouracil (5-FU) forms the backbone for almost all chemotherapeutic regimens 
for CRC (69). However, a subset of CRC patients who develop cancer with microsatellite 
instability or defective mismatch repair (dMMR) show resistance to 5-FU (70,71). Studies 
have shown that dMMR CRC patients with stage III tumors do not benefit from 5-FU-based 
adjuvant (FOLFOX) therapy (70,72). In accordance with clinical observations, in vitro 
studies have shown that dMMR CRC cells are resistant to the cytotoxic effects of 5-FU 
(73). Therefore, elucidating the mechanisms of 5-FU resistance in dMMR CRC and 
identifying novel therapeutic targets to increase the efficacy of 5-FU in dMMR CRC 
represents an unmet need.  
Though the mechanism of actions of 5-FU is not completely understood, its 
cytotoxicity has been ascribed to the inhibition of thymidylate synthase (TS), the key 
enzyme of de novo pyrimidine biosynthesis (74). However, numerous studies have 
established that 5-FU metabolites can induce cytotoxicity through incorporation into RNA 
and genomic DNA (75,76), and that both DNA Mismatch Repair (MMR) and Base Excision 
Repair (BER) pathways are primarily involved in the repair of the resultant DNA lesions 
(76,77). In the case of FU incorporation opposite dG, the resulting FU:dG mispair would 
be efficiently processed by the MMR pathway, resulting in single-stranded breaks (SSBs) 
(77,78). However, repeated incorporation of FU:dG leads to futile attempts by the MMR 
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system and persistent SSBs will result in double-strand breaks that in turn induce 
apoptosis (79). On the other hand, the BER pathway is able to directly remove FU from 
newly synthesized DNA in the case of FU:dA or FU:dG (76,80), resulting in 
apurinic/apyrimidinic (AP) sites that are further processed by AP-endonuclease (APE1) 
(2). APE1 plays a central role in the BER pathway by cleaving the DNA backbone 
immediately 5’ to lesions (35,81). The resulting strand breaks are repaired via the highly 
coordinated BER pathway (82). We have recently shown that APE1 is acetylated (AcAPE1) 
at AP sites in chromatin by p300 and that acetylation enhances its AP-endonuclease 
activity (38,83). We hypothesize that dMMR CRC cells have an increased requirement of 
BER pathway for efficient repair of 5-FU-induced DNA damages, and that targeting APE1-
dependent BER pathway will sensitize dMMR CRC to 5-FU.  
In this study, we sought to examine the role of BER pathway in promoting 5-FU 
resistance in CRC cells with deficient MMR system. We found that downregulation of 
APE1 sensitizes dMMR CRC cells to 5-FU in vitro.  Furthermore, we identified FACT 
complex as an interacting partner of APE1 in chromatin and characterized the role of 
FACT complex in BER pathway. Curaxins, a class of small molecules that inhibit FACT 
complex, were tested extensively in combination with 5-FU using multiple dMMR CRC cell 
lines in vitro and in vivo as a means of improving 5-FU therapeutic response. To provide 
further support of potential applicability of this novel therapeutic strategy, we examined 
the expression of APE1 and FACT in CRC patient specimens and correlated with the 
treatment response. Together, our study unveils a novel role of FACT complex in 
promoting 5-FU resistance, and demonstrates that targeting FACT with curaxins is a 




Materials and methods 
Cell culture, plasmids, siRNAs, transfection and treatments 
HCT116 cells (ATCC# CCL-247) were grown in McCoy’s 5A medium (Gibco) 
supplemented with 10% fetal calf serum (FCS; Sigma) and antibiotic mixture of 100 U/ml 
penicillin and 100 µg/ml streptomycin (Gibco). HCT116 cell line stably expressing APE1-
shRNA was a kind gift from Dr. Sheila Crowe (University of California, San Diego) and 
was cultured in McCoy’s 5A supplemented with 0.01% puromycin (Gibco). HEK-293T cells 
(ATCC # CRL-3216) were cultured in DMEM-high glucose medium (Gibco) with 10% fetal 
calf serum (FCS; Sigma) and antibiotic mixture of 100 U/ml penicillin and 100 µg/ml 
streptomycin (Gibco). RKO cell line was obtained from Dr. Jing Wang (Eppley Institute, 
UNMC). RKO and DLD-1 cells (ATCC# CCL-221) were grown in EMEM medium (ATCC). 
All cell lines were authenticated using STR DNA profiling by Genetica DNA laboratories 
(Burlington, NC) two years ago before being used in this study. These cells were routinely 
assayed for mycoplasma. Mutation of Lys residue (K6, 7, 27, 31 and 32) to arginine or to 
glutamine in APE1-FLAG-tagged pCMV5.1 plasmid were generated using a site-directed 
mutagenesis kit (Agilent-Stratagene, Santa Clara, CA) as described previously (38). 
Exponentially growing HEK293T cells were transfected with wild type (WT) APE1, 
K6,7,27,31,32 to arginine (K5R) or to glutamine (K5Q), N-terminal 33 amino acid deleted 
(N∆33) mutants expression plasmids. siRNAs targeting SSRP1 (Sigma, EHU015991) and 
SPT16 (Sigma, EHU039881; Dharmacon, J-009517), as well as control siRNA 
(Dharmacon, D-001810) were transfected into RKO, HCT116, and HCT116APE1shRNA. 
APE1 siRNAs were obtained from Sigma-Aldrich (WD04424567) and Dharmacon (J-
010237). Cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and 
harvested after 48 hrs. Methyl Methanesulfonate (MMS), quinacrine (QC), and 5-FU were 
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obtained from Sigma-Aldrich. CBL0137 was obtained from Cayman Chemical for in vitro 
study, and from Incuron, LCC (Buffalo, NY) for in vivo study. 
Identification of interacting proteins of AcAPE1  
Chromatin extracts were immunoprecipitated (IP) with anti-AcAPE1 and control 
IgG antibodies (38). The IP samples were boiled for 5 min and resolved in 12.5 % SDS-
PAGE gel followed by staining with Coomassie blue (PageBlue™, Thermo Scientific). 
Identification of protein bands was performed by MALDI-TOF-TOF analysis in the Mass 
Spectrometry and Proteomics Core Facility (University of Nebraska Medical Center, 
Omaha, NE, USA).  
Western Blot Analysis 
Cell fractionation was performed as described previously (81). Whole cell lysates 
or cell fractions were resolved on 10 to 12.5 % SDS-PAGE gel and transferred to nylon 
membranes for blotting. Whole cell lysates of HCEC, GEO, LoVo and SW620 were 
provided by Dr. Jing Wang (UNMC). Primary antibodies were used including SPT16 
(Abcam, 204343), SSRP1 (Biolegend, 609702), FLAG (Sigma, F1804), TRF1 (Abcam, 
10579), α-HSC70 (B6-Sc7298, Santa Cruz Biotechnology), H2A (Abcam, 26350), APE1 
(Novus Biologicals, NB100-116), α-tubulin (Abcam, 52666) and AcAPE1 (35,84). 
Immunoblot signals were detected using Super Signal West pico chemiluminescent 
substrate (Thermo Scientific) after treating with HRP-conjugated secondary Ab (GE 
Healthcare). 
MTT assay 
Cells were seeded at a density of 5 × 103 in 96-well plates. After 24-hour incubation 
in the medium to allow for cell attachment, the fresh medium was added and cells were 
treated with vehicle control (DMSO alone) or indicated doses of 5-FU dissolved in DMSO 
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for 72 hours. The MTT reagent (Sigma-Aldrich, M5655) was added to a final concentration 
of 0.5 mg/ml to each well. The assay was performed as per manufacture’s protocol. Three 
independent experiments with six replicates were performed for each group. 
Patient tissue samples and analysis 
Colon cancer samples were obtained from tissue bank at University of Nebraska 
Medical Center (UNMC) and University of Texas Medical Branch. Tissues were collected 
in accordance with institution's review board approval and informed consent was waived. 
The deparaffinized sections were stained per standard IHC protocol. The antibodies used 
were: AcAPE1 (1:200), Ki67 (1:500, CST, 9027) and SSRP1 (1:100). Staining intensity 
and percentage of positive cells were analyzed by Definiens Releases Tissue Studio® 4.3. 
We used a stain deconvolution algorithm to separate the DAB chromogen stain and the 
hematoxylin counterstain in all tissue cores. We then measured the brown chromogen 
intensity across all tissues to obtain the range of pixel density. Based on the range, we 
divided the staining intensity into 3 categories using one third threshold increment in the 
range. Tissue lysates were prepared and analyzed by Western Blot as described 
previously (44). 
Treatment response is assessed by clinician using modified Ryan Tumor 
Regression Grading System (85). 
Complete response: no viable cancer cells 
Moderate response: small groups of cancer cells 
Minimal response: residual cancer outgrown by fibrosis 




Immunoprecipitation (IP) and FLAG-IP 
Nuclear and chromatin extracts of HCT116 or RKO cells were pre-cleared with 
protein A/G Plus agarose beads and IP was performed with AcAPE1 antibody or control 
IgG (Santa Cruz, sc-2003). The chromatin extracts of control and MMS-treated cells were 
immunoprecipitated with the same antibody. FLAG-IP was done with mouse monoclonal 
α-FLAG M2 antibody-conjugated agarose beads (Sigma-Aldrich, A2220) in nuclear 
extracts of HEK293T cells transfected with FLAG tagged constructs as described 
previously (84). The immunoprecipitated proteins were resolved in SDS-PAGE and 
identified by Western Blot analysis with the indicated antibodies.  
Immunofluorescence 
Cells grown on coverslips were fixed with 4% formaldehyde (Sigma-Aldrich) and 
stained with immunofluorescence as described previously (38). Primary antibodies used 
were mouse monoclonal anti-APE1 (1:100; Novus Biologicals, NB100-116), anti-AcAPE1 
(1:50), SSRP1 (1:100; Biolegend, 609702), SPT16 (1:50; Abcam, 204343). Images were 
acquired by use of a fluorescence microscope with a 63× oil immersion lens (LSM 510; 
Zeiss), and structured illumination microscopy (SIM) was done with an Elyra PS.1 
microscope (Carl Zeiss) by using a 63× objective with a numerical aperture of 1.4. ImageJ 
software was used to measure Manders colocalization using the JaCoP plug-in. 
Chromatin Immunoprecipitation (ChIP) Assay 
ChIP assay was performed after double crosslinking of cells with disuccinimidyl 
glutarate and formaldehyde, with protein A/G Plus agarose beads (Santa Cruz, sc-2003) 
using with AcAPE1, SPT16 and control IgG (Santa Cruz) following the procedure as 
described earlier (38,84). The immunoprecipitated purified DNA was used to amplify the 
p21 and DTL promoter regions using SYBR GREEN-based (Thermo Scientific) Real Time 
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PCR analysis. The following primers are used: p21 forward 5’-
CAGGCTGTGGCTCTGATTGG-3’, reverse 5’-TTCAGAGTAACAGGCTAAGG-3’; DTL 
forward 5’-TCCTGCAAATTTCCCGCAAC-3’, reverse 5’- 
GGCTATGGCGAACAGGAACT-3’. Data were represented as relative enrichment with 
respect to IgG control based on 2−ΔCT method. 
AP site measurement assay 
HCT116 cells were transfected with control and siRNA against SSRP1 and SPT16. 
After 48 hrs, cells were treated with 1 mM MMS for 1 hr and released in fresh media for 6 
hrs. Total genomic DNA was isolated by Qiagen DNeasy kit following manufacturer’s 
protocol. AP sites were measured using aldehyde reactive probe (Dojindo Laboratories) 
as described previously (38). 
Fluorescence Recovery after Photobleaching (FRAP) 
N-terminal GFP tagged -APE1 (86) was transfected into HCT116 cells. 24 hours 
after transfection of control and FACT siRNAs, cells were treated with DMSO or MMS. 
FRAP experiments were performed as described previously (87). All FRAP data were 
normalized to the average prebleached fluorescence after removal of the background 
signal. The curve was plotted using GraphPad Prism 7 and each curve represented an 
average of 10 measurements from different regions of cells. 
Xenograft studies 
All animal experiments were performed following the approval of Institutional 
Animal care and use committee (IACUC). The experiments and reports are adhered to the 
Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines. HCT116 and 
DLD-1 cells (1×106 in 100 μL medium) were injected subcutaneously over the left and right 
flanks in 6-week old male athymic nude mice (Charles Rivers, Wilmington, MA). The 
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average weight was 27 ± 3.6 grams. Subcutaneous tumors were allowed to grow for 1-2 
weeks before treatments. When tumor volume reaches 100 mm3, the mice were randomly 
divided into four treatment groups (each groups n=5 mice) and received treatments every 
other day for three weeks. The following drugs: 5-FU 20 mg/kg, QC 50 mg/kg, CBL0137 
30 mg/kg were injected intraperitoneally. Combination group received both 5-FU and QC 
or CBL0137 100 μL PBS was given to control group. Body weight and tumor volume were 
measured and recorded before each treatment. The mice were euthanized in gas canister 
with gradual fill carbon dioxide after the end of treatment cycles. Xenograft tumor was 
fixed in formalin and paraffin-embedded tissue sections were used to perform IHC staining 
Ki67 and TUNEL assay. The percentage of positive staining was quantified with 10 
random high-power field images from three different sections using TMARKER (88). 
Additive or synergistic effect was examined using online tool SynergyFinder 
(https://synergyfinder.fimm.fi) (89). 
Statistical analysis 
Results are shown as the mean ± SEM of three independent experiments. Shapiro-
Wilk test was used to test for normality distribution. If the Sig. value of the Shapiro-Wilk 
Test is greater than 0.05, the data is considered normal. For comparison among multiple 
groups, one-way analysis of variance (ANOVA) followed by Dunnett's post-hoc test or 
Tukey's HSD test was used depending on the nature of comparison. Student’s t test was 
applied if only two groups were compared. When there were more than one continuous 
dependent variables, one-way multivariate analysis of variance (one-way MANOVA) was 
used to determine whether there were any differences between independent groups. If 
data did not distribute normally, Kruskal-Wallis test followed by Games-Howell post-hoc 
test was used as a non-parametric counterpart of ANOVA for multiple comparison, and 
Mann-Whitney U test as counterpart of Student’s t test for two group comparison. 
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Statistical analyses were performed in SPSS v22.0 (IBM SPSS Statistics). A p-value of 







Downregulation of APE1 sensitizes dMMR CRC cells to 5-FU in vitro 
To examine the role of APE1 in promoting 5-FU resistance in CRC, we used highly 
5-FU resistant dMMR colon adenocarcinoma HCT116 (73) and isogenic HCT116 cells 
expressing APE1-specific shRNA (38). We found that downregulation of APE1 sensitized 
HCT116 to 5-FU (Fig. 4). This phenomenon was confirmed in DLD-1 and HCT116 by 
siRNA interference (Fig. 5), as evidenced by a decrease in the IC50 by approximately 10-
fold (Fig. 6).  
 
 
Figure 4. APE1 shRNA significantly enhances 5-FU cytotoxicity in HCT116 cells.  
To investigate whether APE1 plays a role in 5-FU resistance in colon cancer, HCT116 
cells stably expressing control (ctrl) shRNA or APE1-shRNA were treated with various 
doses of 5-FU for 72 hours. HCT116 is a mismatch repair deficient cell line and highly 
resistant to 5-FU. Viable cells were quantitated in six replicates for each dose by MTT 
assay (Left). To verify the successful knockdown of APE1, the level of APE1 was 
measured by immunoblot analysis (Right), which demonstrated significant decrease of 
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APE1 level with shRNA. As shown in MTT assay, cell viability significantly reduced after 
APE1 knockdown. Results are shown as the mean ± SEM of three independent 
experiments. One-way ANOVA with Dunnett's post-hoc test, *** p<0.001, **** p<0.0001.  
 
 
Figure 5. APE1 siRNA significantly enhances 5-FU cytotoxicity in HCT116 and DLD1 
cells.  
To further confirm our finding from Figure 4, we used siRNA to knockdown APE1 level in 
HCT116 and DLD-1 cells. Both HCT116 and DLD-1 are mismatch repair deficient cell lines 
and highly resistant to 5-FU. Cells were exposed to 5-FU for 72 hours and MTT assay was 
performed. Immunoblot image showing the levels of APE1 after siRNAs transfection has 
decreased significantly, indicating successful knockdown of APE1 (Right). Note that two 
different siRNAs of APE1 are used, both of which showed successful knockdown of APE1 
in either cell line. Consistent with prior experiment, we noted APE1 knockdown 
significantly enhanced 5-FU cytotoxicity. Yellow asterisks mark the comparison between 
HCT116-ctrl siRNA and HCT116-APE1 siRNA. Red asterisks mark the comparison 
between DLD1-ctrl siRNA and DLD1-APE1 siRNA. Six technical repeats were performed 
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per sample and three biological replicates for each siRNA were analyzed. Results are 
shown as the mean ± SEM. One-way ANOVA with Dunnett's post-hoc test, ** p<0.01, *** 
p<0.001, **** p<0.0001. 
 
 
Figure 6. IC50 of 5-FU drops markedly after APE1 knockdown in HCT116 and DLD-1 
cells.  
We used GraphPad to fit a dose response curve to determine the IC50. Line charts 
illustrating a ~10-fold drop in IC50 of 5-FU after APE1 knockdown by shRNA or siRNA. 
Figure 4-6 together demonstrated apparent change of 5-FU efficacy after APE1 
knockdown, suggesting that APE1 plays a key role in 5-FU resistance which provides 
rationale for the following studies.  
 
APE1 interacts with nucleosome remodeling histone chaperone FACT complex in 
chromatin  
In the absence of highly selective and nontoxic small molecule inhibitors of DNA 
repair function of APE1 (90), we set out to identify targets that regulate APE1 function in 
cells. To identify the interacting partners of AcAPE1, we immunoprecipitated (IP) 
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endogenous AcAPE1 from the chromatin fraction using our AcAPE1-specific antibody. 
After separation in SDS-PAGE followed by identification of protein bands by MALDI-TOF-
TOF analysis, we identified a large number of proteins involved in the repair of damaged 
DNA as the prominent AcAPE1 interacting partners (Fig. 7).  We found DNA Ligase III, 
PARP1, both subunits (SPT16 & SSRP1) of FACT complex, nucleolin, chromatin 
assembly factor 1a (CHAF1a), and all four core nucleosome histones H2A, H2B, H3 and 
H4 in the AcAPE1 IP complex. We focused on the FACT complex because increasing 
evidence suggests that FACT complex plays a role at sites of UV damage and single-
strand breaks (SSBs) in cells (91,92). FACT complex, a heterodimer of Structure-Specific 
Recognition Protein1 (SSRP1) and Suppressor of Ty (SPT16), was originally identified as 
a histone chaperone complex that facilitates the removal and deposition of histone 
H2A/H2B in nucleosome during transcription initiation and elongation (63,93). We 
confirmed the interaction of AcAPE1 with FACT complex by immunoprecipitating AcAPE1 
from nuclear and chromatin extracts followed by Western blot analysis. We found both 
subunits of FACT in AcAPE1 IPs, in both chromatin and nuclear fractions (Fig. 8). 
Confocal microscopy revealed colocalization of AcAPE1 with SPT16 and SSRP1 in the 
nucleus (Fig. 9). To examine whether acetylation of APE1 is required for its interaction 
with FACT complex, we immunoprecipitated FLAG-tagged WT-APE1 and nonacetylable 
K5R mutant from nuclear fractions. No significant differences were observed in the amount 
of SPT16 bound with WT and non-acetylable K5R APE1 IPs, indicating that acetylation of 
APE1 is not essential for its interaction with FACT complex (Fig. 10). We also used the 
FLAG-tagged N-terminal 33 amino acids deleted NΔ33 mutant and K5Q APE1 mutant 
which cannot enter the nucleus and stably bind to chromatin in cells (38,86). Our data 
showed that inhibition of either nuclear localization or chromatin binding of APE1 
significantly reduced the amount of SPT16 or SSRP1 in APE1 IP (Fig. 10). Together, 
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these data indicate that APE1 forms complex with FACT in chromatin, and acetylation is 
not essential for this interaction.  
 
Figure 7. IP of endogenous AcAPE1 reveals both subunits of FACT complex as 
interacting partner.  
To identify the interacting partners of AcAPE1 in chromatin, endogenous AcAPE1 was 
immunoprecipitated from chromatin extracts and resolved in SDS-PAGE gel followed by 
MALDI-TOF/TOF analysis. We identified multiple proteins, including H2A, H2B, H3, H4, 





Figure 8. Co-IP of AcAPE1 in nuclear and chromatin extracts confirms the 
interaction of AcAPE1 with FACT complex.  
To confirm our unbiased mass spec. approach of finding of AcAPE1 and FACT interaction, 
we used co-IP with AcAPE1 antibody followed by Western blot analysis which showed the 




Figure 9. Confocal microscope demonstrates the colocalization of AcAPE1 and 
FACT complex.  
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Consistent with co-IP and western blot analysis, we visualized the colocalization of 
AcAPE1 with SPT16 and SSRP1 using confocal microscope. Note that the colocalization 
is located in nuclei only. Three biological replicates were analyzed. Representative images 
were shown. Bar = 50 μm.  
 
 
Figure 10. APE1 forms complex with FACT, and acetylation is not essential for this 
interaction. 
 (Left) Schematic diagram showing the mutation (red) and deletion sites in the N-terminus 
of APE1. Lysine residues K6,7,27,31,32 were mutated to glutamine (K5Q) or arginine 
(K5R) in FLAG-tagged WT APE1 using a site-directed mutagenesis Kit (Stratagene). Both 
K5Q and K5R are nonacetylable mutants of APE1, with the latter maintains a positive 
charge. To examine whether acetylation of APE1 is required for its interaction with FACT 
complex, we immunoprecipitated FLAG-tagged WT-APE1 and nonacetylable K5R mutant 
from whole cell extract. No significant differences were observed in the amount of SPT16 
bound with WT and non-acetylable K5R APE1 IPs, indicating that acetylation of APE1 is 
not essential for its interaction with FACT complex. In comparison, K5Q had less 
association with FACT complex in the IP complex, indicating a role of positive charge in 
the interaction. We also used the FLAG-tagged N-terminal 33 amino acids deleted NΔ33 
mutant and found that inhibition of localization significantly reduced the amount of SPT16 
or SSRP1 in APE1 IP. Together, these data indicate that APE1 forms complex with FACT 
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in chromatin. While acetylation is not essential for this interaction, positive charge of APE1 
may play a role. 
 
Induction of AP sites enhances colocalization of AcAPE1 and FACT in chromatin 
To determine whether induction of DNA damage promotes interaction of APE1 and 
FACT at damage sites, we generated AP sites in the genome by 5-FU or MMS treatment 
(a widely used alkylating agent that induces AP sites in the genome) (94). Structured 
Illumination Microscopy (SIM) revealed enhanced colocalization of both subunits of FACT 
complex with APE1 or AcAPE1 upon treatment (Fig. 11 & 12). The Pearson correlation 
coefficient (PCC) was used to quantify the degree (+1 perfect correlation to -1 perfect but 
negative correlation) of colocalization between fluorophores (Fig. 13). There was 
significant increase of colocalization of APE1 or AcAPE1 with FACT complex upon 
induction of DNA damages, raising the possibility that recruitment of FACT to the damage 
sites may promote binding and acetylation of APE1 during the DNA repair process. We 
examined the levels of FACT and AcAPE1 in chromatin fraction at several time points 
following MMS treatment. Treatment of MMS resulted in increasing levels of AcAPE1 and 
both subunits of FACT complex in chromatin fraction in a time-dependent manner (Fig. 
14). Our Co-IP data showed that there was an increasing association of AcAPE1 and 
FACT complex upon induction of DNA damage (Fig. 15). Previously, we showed that 
APE1 regulates p21 expression via binding to the p21 and DTL proximal promoter regions 
and functions as a coactivator or corepressor depending on the p53 status of the cells 
(95). To understand if FACT facilitates the recruitment and/or binding of APE1 to damage 
sites in p21 and DTL promoters, we treated the cells with MMS and cross-linked the 
chromatin. We performed ChIP assays with AcAPE1 and SPT16 antibodies. We found 
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that induction of DNA damage significantly increased the binding/occupancy of AcAPE1 
and SPT16 to the p21 and DTL gene promoter regions (Fig. 16). 
 
 
Figure 11. Colocalization of AcAPE1 and FACT complex increases upon induced 
DNA damages.  
To investigate whether induced DNA damage affects the interaction, HCT116 cells were 
treated with MMS (1 mM) for 30 minutes or 5-FU (10 μM) for 24 hours and cells were fixed 
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with paraformaldehyde submitted for immunofluorescence staining. Colocalization of 
SSRP1 or SPT16 with AcAPE1 was examined in multiple cells by Structured-Illumination 
Microscopy (SIM). MMS and 5-FU significantly induced the interaction of AcAPE1 and 
FACT complex. Three technical repeats were performed per sample and three biological 
replicates were analyzed. Representative images were shown. Bar = 5 μm. 
 
 
Figure 12. Colocalization of APE1 and FACT complex remains unchanged upon 
MMS treatment.  
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Following the above immunofluorescence analysis, we examined if MMS has effects on 
the interaction of APE1 (instead of acetylated form of APE1) and FACT. HCT116 cells 
were treated with MMS for 30 minutes or 5-FU for 24 hours. The colocalization of APE1 
with SPT16 and SSRP1 remained stable without detectable changes under SIM. Three 
technical repeats were performed per sample and three biological replicates were 








Figure 13. Pearson correlation coefficient of AcAPE1 and FACT complex increases 
upon induction of DNA damages.  
To quantify the colocalization of the proteins of interest, we used Pearson correlation 
coefficient (PCC) which is a measure of the strength of the association between the two 
variables (96). The correlation coefficient ranges from −1 to +1, with +1 being perfect 
correlation and -1 being perfect but negative correlation. PCC of AcAPE1 and SSRP1 or 
SPT16 increased significantly upon induction of DNA damages either by MMS (top panel) 
or 5-FU (middle panel). The change in PCC of APE1 with SSRP1 or SPT16 did not 
demonstrate any statistical significance (bottom panel). Data from ten cells were analyzed. 
Top and bottom panels, MANOVA with Tukey's HSD test; middle panel, Student’s t test; * 
p=0.035; *** p<0.001. 
 
Figure 14. MMS treatment increases the expression of FACT complex and AcAPE1 
in chromatin fraction.  
To investigate whether MMS treatment has an effect on the AcAPE1 and FACT complex 
expression, HCT116 cells were treated with 1 mM MMS for various time periods as 
indicated. AcAPE1, SSRP1 and SPT16 proteins levels increased in chromatin extracts 




Figure 15. Interaction of AcAPE1 and FACT complex increases upon induction of 
DNA damages.  
To understand if MMS treatment increases the association between AcAPE1 and FACT 
complex, HCT116 cells were treated with 1 mM MMS and the chromatin extract was 
immunoprecipitated with AcAPE1 antibody, followed by immunoblot analysis of SSRP1 
and SPT16 antibodies (Top). MMS significantly induced the interaction of AcAPE1 and 
SSRP1 as well as SPT16. (Bottom) Quantification SPT16 and SSRP1 in IP was done by 
Image J software and average of three independent co-IP experiments demonstrated that 
the fold change of SSRP1 and SPT16 levels before and after MMS treatment. MANOVA 






Figure 16. Occupancy of AcAPE1 and SPT16 to p21 and DTL promoter regions 
significantly increases upon MMS treatment.  
To understand whether MMS treatment affects the occupancy of AcAPE1 and SPT16 to 
p21 and DTL promoter regions, cells were treated with 1 mM MMS and fixed with 
formaldehyde. Protein-DNA was crosslinked, followed by lysis of cells. Chromatin was 
harvested and fragmented, which was then subjected to immunoprecipitation with 
AcAPE1 and SPT16 antibodies. PCR of p21 and DTL sequences revealed that the binding 
of AcAPE1 and SPT16 significantly increased upon MMS treatment. Three technical 
repeats were performed per sample and three biological replicates were analyzed. Results 
are shown as the mean ± SEM. The difference was noted both at 10 minutes and 1-hour 




FACT complex facilitates the binding and acetylation of APE1 to damage site in 
chromatin. 
To examine if FACT is required for facilitating the binding and acetylation of APE1 
at damage sites in chromatin, we used siRNA to downregulate SPT16 and SSRP1 
individually and both together (Fig. 17). Consistent with prior report, we found that 
downregulation of either subunit SPT16 or SSRP1 affected the level of the other subunit 
in cells (97). We found a significant decrease of AcAPE1 level when both subunits of FACT 
were downregulated (Fig. 17). SIM demonstrated that FACT knockdown reduced the 
AcAPE1 level but did not alter total APE1 level in cells (Fig. 18 & 19). As acetylation of 
APE1 occurs after binding to AP site in chromatin, these data indicate that the absence of 
FACT complex significantly reduced the access or binding of APE1 to damage sites and 
its subsequent acetylation in chromatin. We examined the binding or occupancy of 
unmodified APE1 and AcAPE1 to p21 and DTL promoter in FACT downregulated cells by 
ChIP assays. ChIP assays revealed that FACT downregulation significantly abrogated the 
occupancy of APE1 and AcAPE1 to p21 and DTL promoters upon DNA damages (Fig. 20 
& 21). Together, these data provide evidence that the FACT complex promotes the 
binding and subsequent acetylation of APE1 to damage sites in chromatin.  
To further examine the role of FACT in regulating APE1 binding dynamics to 
damage sites, we used Fluorescence Recovery After Photobleaching (FRAP) (98) to 
quantify the mobility of GFP-tagged APE1 in the presence or absence of FACT complex. 
Fluorescence was bleached using an excitation laser, and the recovery of fluorescence in 
that region due to binding of new GFP-tagged APE1 into chromatin was monitored (98). 
The mobile fraction represents the fraction of recovered fluorescence and the half-life (T1/2) 
is the time it takes for fluorescence intensity to reach half the maximum of the plateau 
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level. In the presence of MMS, the mobile fraction of APE1 in FACT downregulated cells 
was significantly lower compared to control cells (Fig. 22), suggesting that FACT regulates 




Figure 17. FACT KD decreases the level of AcAPE1 but has no effect on total APE1 
level.  
To examine if FACT is required for facilitating the binding and acetylation of APE1 at 
damage sites in chromatin, HCT116 cells were transfected with SPT16 or SSRP1 siRNA 
individually or both together (FACT) and the levels of AcAPE1 and APE1 were measured 
by Immunoblot analysis after 48 hours. Note that FACT siRNA means siRNAs of SSRP1 
plus SPT16. We found that KD of either unit, SPT16 or SSRP1, decreased the AcAPE1 
level (more apparent in SSRP1 KD cells). Such effect was most evident when both 
subunits of FACT complex were depleted. We also found that the APE1 level had stayed 
unchanged with SPT16 and/or SSRP1 treatment. Three biological replicates were 





Figure 18. AcAPE1 level decreases upon knockdown of FACT complex.  
To confirm our finding of the effect of FACT KD on APE1 and AcAPE1 levels, we used 
immunofluorescence staining. SPT16 or SSRP1 level individually or both together (FACT) 
was downregulated by siRNA for 48 hours and the levels of AcAPE1 and APE1 were 
examined by immunofluorescence. The decrease in the fluorophores detected in SPT16 
and SSRP1 staining cells proves successful knockdown. Images of one representative 
cell is shown. Consistent with our IP result, the AcAPE1 staining reduced markedly after 





Figure 19. APE1 expression remains unchanged upon FACT KD.  
This is in continuation of the previous experiment. After we demonstrated that FACT KD 
had no effect on total APE1 level by IP, we sought to confirm this finding using 
immunofluorescence staining. As compared to control cells, FACT KD cells demonstrated 
no change in staining of APE1. Three biological replicates were analyzed. Representative 
images were shown. As acetylation of APE1 occurs after binding to AP site in chromatin, 
these data (Fig. 17-19) indicate that the absence of FACT complex significantly reduced 





Figure 20. FACT KD prevents the increase of occupancy of AcAPE1 to p21 and DTL 
promoter regions upon MMS treatment.  
Earlier we have shown that induction of DNA damage by MMS significantly increased the 
binding of AcAPE1 to p21 and DTL promoter regions (Fig. 16). We also showed that FACT 
KD had decreased the binding and subsequent acetylation of APE1 at chromatin. To 
assess if FACT KD affects the occupancy of AcAPE1 to p21 and DTL promoters, cells 
were treated with FACT siRNA for 48 hours and 1 mM MMS treatment for 1 hour, followed 
by ChIP analysis. Consistent with our prior result, MMS treatment increased the binding 
of AcAPE1 to p21 and DTL promoter regions. However, this effect was abrogated by 
depletion of FACT complex. Yellow asterisks mark the comparisons between ctrl siRNA 
and FACT siRNA without MMS treatment. This indicates that FACT KD alone (without 
induced DNA damage by MMS) decreases the AcAPE1 occupancy to both promoter 
regions, suggesting a role of FACT in the access and binding of AcAPE1 in normal cellular 
process. Red asterisks mark the comparisons between ctrl siRNA and FACT siRNA at the 
presence of MMS. This indicates that the effect of increased AcAPE1 occupancy induced 
by MMS is blunted if FACT complex is depleted, and further confirms the role of FACT 
complex in the access and binding of AcAPE1 to chromatin. Average enrichment relative 
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to % of input from three independent ChIP assays were shown. One-way ANOVA with 
Tukey's HSD test, ** p<0.01, *** p<0.001. 
 
 
Figure 21. FACT KD prevents the increase of occupancy of APE1 to p21 and DTL 
promoter regions upon MMS treatment.  
The previous ChIP analysis use antibody targeting acetylated APE1. However, the total 
APE1 may have different binding and occupancy to p21 and DTL promoter regions. 
Therefore, we performed ChIP analysis using total APE1 antibody which identifies all 
forms of APE1 in cells including acetylated APE1. There was some variation of how the 
APE1 occupancy changed in response to FACT knockdown and MMS treatment 
compared to the analysis where we used AcAPE1 antibody. The trend of changes, 
however, was consistent. As noted in the above figure, MMS treatment increased the 
APE1 occupancy to both promoter regions. When FACT complex was depleted, the APE1 
occupancy reduced significantly which was marked as yellow asterisks (ctrl siRNA vs 
FACT siRNA without MMS treatment). Red asterisks mark the comparisons between ctrl 
siRNA and FACT siRNA at the presence of MMS, which demonstrated significant 
reduction of APE1 binding/occupancy to these promoter regions despite MMS induced 
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damage. Average enrichment relative to % of input from three independent ChIP assays 
data were shown. One-way ANOVA with Tukey's HSD test, * p<0.05, ** p<0.01, *** 




Figure 22. APE1 dynamics decreases after FACT KD.  
Fluorescence recovery after photobleaching (FRAP) is a microscopy-based method used 
to study the mobility of fluorescent molecules. To determine if FACT complex plays a role 
in the mobility of APE1, N-terminal GFP tagged-APE1 was transfected into HCT116 cells. 
48 hours after transfection of control and FACT siRNAs, cells were treated with DMSO or 
MMS. Specific regions were bleached with laser and the recovery of GFP fluorescence 
was examined. As expected, MMS treatment increased APE1 mobility while FACT KD 
decreased it. In FACT KD cells, however, the mobility of APE1 failed to increase despite 
MMS treatment, indicating that FACT complex facilitates the access and mobility in 
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damage regions. We performed FRAP experiments on at least 20 cells per condition and 
three biological replicates were performed. Individual FRAP measurement curves were 
averaged to get a single FRAP curve (99). One-way ANOVA with Dunnett's post-hoc test, 
**** p<0.0001. 
 
FACT is required for efficient repair of AP site damages in cells and downregulation 
of FACT sensitizes CRC cells to 5-FU  
As FACT promotes binding and subsequent acetylation of APE1, we deduced that 
cells would accumulate AP sites in the absence of FACT. We depleted FACT complex by 
siRNA and quantitated AP sites in the genome. As expected, depleting FACT complex 
significantly increased the number of AP sites in the genome compared to control (Fig. 
23). We also treated these cells with MMS to induce AP site damages. As shown in Fig. 
23, AP sites accumulated significantly in the genome after MMS treatment in both control 
and FACT downregulated cells. However, after 6 hours of release, FACT knockdown cells 
retained significantly more AP sites, indicating that efficient AP site repair depends on the 
function of FACT complex. To provide further evidence for the role of FACT in facilitating 
the AP site or SSBs repair in cells, we used single cell alkaline comet assay which detects 
the SSBs and DSBs damages in the genome in cells. Knockdown of FACT significantly 
delayed the repair of MMS-induced DNA damages in the genome compared to control 
cells (Fig. 24). Consistently, we found that downregulation of FACT sensitizes HCT116 
and RKO cell lines to 5-FU (Fig. 25). Together, these data indicate that FACT complex 




Figure 23. MMS treatment increases AP sites, and FACT KD cells retains 
significantly more AP sites after recovery.  
MMS is a classic BER substrate–generating compound that modifies both guanine (to 7-
methylguanine) and adenine (to 3-methlyladenine) to cause base mispairing and 
replication blocks (100). The damaged bases are removed by glycosylases, producing AP 
sites. To investigate whether FACT complex affects the APE1 repair activity, control and 
FACT downregulated cells were treated with MMS and then release for 6 hours. The 
number of AP sites in the genomic DNA was quantitated using aldehyde reactive probe in 
triplicates under each condition (38). Without MMS to induce AP site, FACT KD cells had 
larger amount of AP sites as compared to control cells, indicating that normal BER function 
requires FACT complex under physiological condition. MMS treatment significantly 
increased the number of AP sites. After 6-hour release, cells were allowed for BER activity 
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and AP sites decreased. However, FACT siRNA treated cells retained significantly more 
AP sites despite 6-hour release, indicating that FACT depletion has negative impact on 
the BER function. This is consistent with our biochemical finding that FACT complex 
facilitates the access and mobility of APE1. Average of three independent experiments is 




Figure 24. FACT KD impairs BER activity after MMS treatment as demonstrated by 
alkaline comet assay.  
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To further examine the effect of FACT complex in BER function, we used alkaline comet 
assay which detects the SSBs and DSBs damages in the genome (101). Control and 
FACT downregulated cells were treated with MMS (1 mM for 30 min) and release for 6 
hours. The DNA damage was quantified by measuring the displacement between the 
comet head (which represent undamaged DNA) and the tail (resulting from damaged 
DNA). The tail moment has been suggested to be an appropriate index of induced DNA 
damage in considering both the migration of the genetic material as well as the relative 
amount of DNA in the tail. MMS treatment induced DNA damage, as reflected by the 
markedly increased tail moment. Cells were allowed for 6-hour recovery and tail moment 
decreased. In contrary, FACT KD cells failed to repair the damages after 6-hour release. 
Average tail moment was calculated from 100 cells using open comet software. One-way 
ANOVA with Tukey's HSD test, ** p<0.01, *** p<0.001, **** p<0.0001. 
 
 
Figure 25. Downregulation of FACT sensitizes HCT116 and RKO cell lines to 5-FU.  
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To examine whether FACT KD sensitizes cells to 5-FU, HCT116 and RKO cells were 
treated with FACT siRNA and exposed to indicated doses of 5-FU for 72 hours. Cell 
viability were examined by MTT assay. FACT KD significantly improved the treatment 
efficacy of 5-FU, starting as low as from 5 μM. Average of three independent experiments 
is shown. One-way ANOVA with Dunnett's post-hoc test, *** p<0.001, **** p<0.0001. 
 
Targeting FACT with curaxins enhances the efficacy of 5-FU in dMMR CRC cells in 
vitro  
Several studies have shown that curaxins, a class of small molecule drugs (Fig. 
26), have broad anticancer activity and function as an inhibitor of FACT complex (102-
104). FACT binds to unfolded nucleosomes and curaxins trap FACT in chromatin (102). 
Consistent with previous studies, our data show that Quinacrine (QC) (105 ), a first 
generation curaxin, reduced SSRP1 and SPT16 levels from soluble nuclear fraction but 
had no effect on the chromatin-bound fraction (Fig. 27). CBL0137, a second generation 
curaxin (106), exhibited a similar effect on FACT complex and decreased the level of 
AcAPE1 while total APE1 level remained unchanged (Fig. 28, 29 & 30). Of note, we found 
that HCT116 cells were unable to repair 5-FU- or MMS induced damage in the presence 
of FACT inhibitor CBL0137 (Fig. 31 & 32). Since our studies and others show that FACT 
is involved in AP site or SSBs repair in cells, we examined whether targeting FACT with 
CBL0137 enhanced the efficacy of 5-FU in dMMR CRC in vitro. To eliminate the possibility 
that QC or CBL0137 show cytotoxic effect per se by inducing DNA damages, cells were 
treated with different doses of QC or CBL0137 alone. We found minimal DNA damage 
with treatment of increasing doses of CBL0137 treatment on comet assay (Fig. 33). 
Moreover, 4 μM CBL0137 or 10 μM QC alone had a minimal effect (20% cell death) on 
cell viability (Fig. 34). However, combination of 2 μM CBL0137 or 5 μM QC with 5-FU 
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significantly enhanced the sensitivity (~50-fold decrease in IC50) of 5-FU resistant dMMR 
HCT116 and RKO cells to 5-FU (Fig. 35), suggesting that targeting FACT complex with 
curaxins could be a promising strategy to overcome 5-FU resistance in dMMR CRC cells 
in vivo.   
 
 
Figure 26. Chemical structures of QC and CBL0137. 
 
 
Figure 27. QC causes chromatin trapping effect on FACT complex.  
To verify the effect of QC, the first generation curaxins, on the expression profile of FACT 
complex, HCT116 cells were treated with indicated doses of QC for 1 hour and whole cell 
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extract (WCE), soluble nuclear and chromatin-bound fractions were prepared. SSRP1 and 
SPT16 levels in theses extracts were examined by immunoblot analysis. QC treatment 
resulted in reduced levels of SPT16 and SSRP1 both in WCE and nuclear extracts. In 
chromatin extract, the opposite effect of QC on SPT16 and SSRP1 levels were noted. This 
is referred to as ‘chromatin trapping’ effect of curaxins. 
 
 
Figure 28. CBL0137 causes chromatin trapping effect on FACT complex and 
decreases AcAPE1 level.  
In continuation of the previous experiment, we used second generation curaxins, namely 
CBL0137, to confirm its effect on FACT complex. HCT116 cells were treated with indicated 
doses of CBL0137 for 1 hour and whole cell extract (WCE), soluble nuclear and chromatin-
bound fractions were prepared. SSRP1 and SPT16 levels in theses extracts were 
examined by immunoblot analysis. A similar effect was noted with CBL0137, in which 
SPT16 and SSRP1 levels decreased in WCE and nuclear extracts while increased in 
chromatin fraction. In addition, we found that the AcAPE1 level decreased upon CBL0137 
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treatment. The total APE1 level, however, remained unchanged. Three biological 
replicates were analyzed. Representative images were shown. 
 
 
Figure 29. CBL0137 decreases the expression level of AcAPE1 in a dose-dependent 
manner.  
The observation that CBL0137 decreased the AcAPE1 level was further confirmed by 
immunofluorescence staining. Cells were treated with indicated doses of CBL0137 for 1 
hour and the AcAPE1 level in cells was examined by SIM. CBL0137 treatment caused 
reduction of AcAPE1 level in a dose-dependent manner. Multiple cells from three 





Figure 30. CBL0137 has no effect on the expression of total APE1.  
We have shown that FACT KD does not affect the total APE1 level. Here, we examined 
the APE1 level in HCT116 cells after treatment with indicated doses of CBL0137. At tested 
doses of CBL0137, the total APE1 level remained unchanged as demonstrated by SIM. 
Multiple cells in three biological replicates were analyzed. Representative images were 






Figure 31. CBL0137 inhibits BER function on 5-FU induced DNA damage repair.  
In previous experiments, we have demonstrated that FACT KD significantly impaired BER 
activity. To investigate whether CBL0137 produces similar inhibitory effect on BER 
function, we pretreated HCT116 cells with CBL0137 for 1 hour. Cells were then exposed 
to 5-FU for 6 hours and allowed to recover for 26 hours. DNA damage was examined by 
alkaline comet assay. In both groups, 5-FU treatment induced a rise in tail moment. As 
compared to control cells which successfully repaired the majority of induced damages at 
26-hour release, CBL0137 treated cells retained the damages despite recovery. Tail 
moment of 100 cells per sample was calculated using open comet software. Three 
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independent biological replicates were analyzed. Results are shown as the mean ± SEM. 
One-way ANOVA with Tukey's HSD test, *** p<0.001, **** p<0.0001. 
 
 
Figure 32. CBL0137 inhibits BER function on MMS induced DNA damage repair.  
BER and MMR are both involved in 5-FU damage repair (discussed in detail in 
Introduction). While the previous experiment showed cells retained 5-FU damage after 
CBL0137 pretreatment, the possibility of MMR being dysfunction cannot be eliminated. In 
continuation of the previous experiment, to provide further evidence that CBL0137 inhibits 
BER repair activity, we pretreated HCT116 cells with CBL0137 for 1 hour. Cells were then 
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exposed to MMS (a classic BER substrate–generating compound) for 30 minutes and 
allowed to recover for 6 hours. DNA damage was examined by alkaline comet assay. 
Consistently, we found that cells failed to repair MMS induced damages after 6-hour 
release. Along the previous experiment, these data suggest that CBL0137 inhibits BER 
repair activity in cells. Tail moment of 100 cells was calculated per sample using open 
comet software. Three biological replicates were analyzed. Results are shown as the 




Figure 33. CBL0137 alone does not induce DNA damage.  
To eliminate the possibility that CBL0137 induce DNA damages which would bias our 
above findings, cells were treated with indicated doses of CBL0137 for 1 hour and alkaline 
comet assay was performed. We found that CBL0137 alone did not induce significant DNA 






Figure 34. QC or CBL0137 alone has minimal effect on cell viability.  
To examine if QC or CBL0137 has inhibitory effect on cell viability, HCT116 and RKO cells 
were treated with QC (Left) or CBL0137 (Right). MTT assays showed that high dose of 
QC (10 μM) or CBL0137 (4 μM) had minimal effect on cell viability. Six technical repeats 
were performed per sample and three biological replicates were analyzed. Results are 
shown as the mean ± SEM. 
 
 
Figure 35. Combination of 5-FU plus curaxins demonstrated synergistic effect on 
inhibition of cell viability.  
61 
 
To investigate whether curaxins sensitizes colon cancer cells to 5-FU, HCT116 and RKO 
were treated with 2 μM CBL0137 (Left) or 5 μM QC (Right) for 1 hour then exposed to 
various doses of 5-FU. RKO is a mismatch repair deficient cell line and intermediate 
resistant to 5-FU. Cell viability was measure in six replicates by MTT assay. We found that 
combination therapy significantly inhibited cell viability and demonstrated synergistic effect. 
Yellow asterisks mark the comparisons between HCT116 and HCT116/CBL0137 (Left) or 
HCT116 and HCT116/QC (Right). Red asterisks mark the comparisons between RKO and 
RKO/CBL0137 (Left) or RKO and RKO/QC (Right). Average of three independent 
experiments are shown. One-way ANOVA with Dunnett's post-hoc test, * p<0.05, ** 
p<0.01, *** p<0.001, **** p<0.0001. 
 
FACT inhibitor Curaxin sensitizes dMMR-CRC tumor to 5-FU in vivo 
To examine whether the combination of curaxins and 5-FU inhibits dMMR-CRC 
tumor growth in vivo, we utilized tumor xenograft models. The effects of QC and CBL0137 
were tested alone and in combination of 5-FU. HCT116 and DLD-1 cells were used to 
generate xenograft models. Tumor growth curve showed that single agent treatment with 
5-FU, QC or CBL0137 alone had very little or moderate effect on tumor growth compared 
to vehicle group (Fig. 36-39), while combination group significantly inhibited tumor growth, 
demonstrating a synergistic effect. The combination of QC with 5-FU was well tolerated at 
the scheduled doses. All mice were weighted at each time point of treatment during the 
study, and there was 10-15% total weight loss at the end of study period. No cachectic 
appearance was noted (Fig. 40). Moreover, no major histological abnormality was 
identified in vital organs including lung, liver and kidney (Fig. 41). Further analysis showed 
that combination group suppressed the proliferation and induced apoptosis in these 
tumors (Fig. 42-43). Additionally, long-term QC treatment resulted in decreased SSRP1 
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level in nucleus and the residual SSRP1 was trapped in chromatin (Fig. 44), suggesting 
that QC alters FACT expression and localization in vivo. These data together demonstrate 
that inhibition of FACT function with curaxins can overcome 5-FU resistance and inhibits 





Figure 36. Combination of 5-FU plus QC significantly inhibits HCT116 xenograft 
growth with synergistic effect when compared to monotherapy of 5-FU or QC.  
To test the treatment efficacy of combination therapy in vivo, one million of HCT116 cells 
(in 100 μL culture medium) were implanted subcutaneously in the flanks of seven weeks 
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old athymic nude male mice to generate xenografts. When average tumor volume reached 
100 mm3, mice were randomized into four groups (n=5 in each group). Vehicle (100 μL 
PBS), 5-FU, QC and combination of 5-FU and QC were administered to mice 
intraperitoneally for 3 weeks. Weight of each mice and tumor size were measured each 
time before treatment and every 3 days after completion of treatment. Tumor volume= (π 
x length x width2) / 6, where length represents the largest tumor diameter and width 
represents the perpendicular tumor diameter. Although we measured the ten xenograft 
tumors’ volume in each group, caution should be taken when interpreting the results as 
we used 5 mice (independent biological samples) in each group; the pair of tumors 
(technical replicates) in each mouse should be considered as one as the 
microenvironment and drug delivery was nearly identical. In our final analysis, we used 
the average volume of the pair of xenografts in the same mice as an independent sample. 
We found that 5-FU or QC alone had minimal inhibitory effect on xenograft growth. This 
is consistent with the fact that HCT116 cells are highly 5-FU resistant. In contrast, when 
combining with QC, 5-FU inhibited tumor growth with significantly (p<0.01) smaller tumor 
volume at the end of the study, demonstrating synergistic effect. The drug combination 
effect was calculated in SynergyFinder to examine the presence of additive or synergistic 






Figure 37. Combination of 5-FU plus CBL0137 significantly inhibits HCT116 
xenograft growth with synergistic effect when compared to monotherapy of 5-FU or 
CBL0137.  
In another experiment, we used CBL0137 to replace QC and repeat the xenograft study. 
One million of HCT116 cells were used to generate xenograft tumors as described above. 
We found that CBL0137 alone had inhibitory effect on tumor growth, as evident from final 
tumor volume. Similar to prior experiment, combination therapy of 5-FU and CBL0137 
exhibited synergistic effect on final tumor volume. Statistical analysis was performed as 







Figure 38. Combination of 5-FU plus QC significantly inhibits DLD-1 xenograft 
growth with synergistic effect when compared to monotherapy of 5-FU or QC.  
To further provide evidence that combination therapy overcomes 5-FU resistance, we 
used DLD-1 cells (5-FU resistant cell line) to perform xenograft study per our protocol. 
One million DLD-1 cells were injected subcutaneously in the flanks of mice. Vehicle, 5-FU, 
QC and combination of 5-FU and QC were administered to mice (n=5) intraperitoneally 
for 3 weeks. While 5-FU alone did not produce significant inhibition on tumor growth, QC 
alone demonstrated statistically significant inhibitory effect. Combination therapy, on the 
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other hand, exhibited superior treatment efficacy with synergistic effect as demonstrated 
by significantly smaller tumor volume at the end of study when compared to monotherapy 
either of 5-FU or QC. Statistical analysis was performed as described in figure 36. Kruskal-





Figure 39. Combination of 5-FU plus CBL0137 significantly inhibits DLD-1 xenograft 
growth with synergistic effect when compared to monotherapy of 5-FU or CBL0137.  
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As CBL0137 has been introduced in clinical phase I and II trials, we are interested in the 
effect of CBL0137. Similar to our prior experiment, we generated xenograft tumor model 
using DLD-1 cells. Vehicle, 5-FU, CBL0137 and combination of 5-FU and CBL0137 were 
administered to mice (n=5) intraperitoneally for 3 weeks. While 5-FU failed to inhibit tumor 
growth as demonstrated by similar tumor volume at the end of the study, we found that 
addition of CBL0137 sensitized the DLD-1 cells to 5-FU and the combination group 
demonstrated synergistic effect on inhibition of tumor growth. Statistical analysis was 
performed as described in figure 36.  Kruskal-Wallis test with Games-Howell post-hoc test, 
* p<0.05, ** p<0.01. 
 
 
Figure 40. Representative xenograft mice picture demonstrates no gross weight 
change noted at the completion of study.  
One of the considerations in the evaluation of treatment effect is the toxicity of drugs. If 
the drug causes severe toxicity, it will lead to weight loss and cachectic appearance. In 
our study, we measured body weight each time before treatment. Representative images 
of mice form each treatment group at the completion of experiment showed no significant 





Figure 41. No major organ toxicity is noted on H&E staining after treatment.  
To examine if the monotherapy or combination drugs has toxicity effect, we harvested 
major organs after completion of the treatment and performed H&E staining. We found 
that there was no alteration of tissue histology in major organs after a series of 3-week 





Figure 42. Combining 5-FU with QC significantly decreases percentage of positive 
Ki-67 staining in xenograft.  
To understand the mechanism of the inhibitory effect of combination therapy, we 
examined proliferative marker (Ki-67) and apoptotic marker (TUNEL staining) in xenograft 
section. The percentage of positive staining cells were quantified with 10 random high-
power field images using TMARKER. On the right side was bar graph depicting the Ki67 
positive cell percentage among groups. We found that monotherapy with QC had some 
inhibitory effect on cell proliferation. Combination therapy demonstrated significant 
reduction of Ki67 staining, indicating that at least part of the effect on tumor growth could 
be attributed to anti-proliferative activity. Data report the mean ± SEM of percentages of 






Figure 43. Combination therapy induces apoptosis in xenograft tumor.  
(Left) TUNEL assay was performed in tumor sections and the representative images are 
shown. (Right) Bar graph depicts the TUNEL positive cell percentage among groups. In 
contrary to the tumor growth result where 5-FU alone had no effect, 5-FU treated group 
had higher percentage of cells undergoing apoptosis when compared to vehicle group. 
Combination therapy induced apoptosis in a significantly higher percentage of cells when 
compared with vehicle or monotherapy. This suggests that the inhibitory effect on 
xenograft growth is partly derived from apoptosis. Data report the mean ± SEM of 







Figure 44. The staining of SSRP1 decreases in the combination treatment group.  
We have provided biochemical evidence that QC causes chromatin trapping of FACT 
complex (Fig. 27). Here, we investigated if such effect could be detected in xenograft 
section. Tumor sections from each treatment groups were stained with SSRP1 antibody. 
Zoomed images of portions of the IHC staining indicate the chromatin trapping of FACT 
complex due to QC treatment. Notably, the combination group markedly decreased the 
expression level of SSRP1. It is an interesting finding that we could not fully understood 
and explained. Indeed, we have verified the finding several times in our animal studies 
and observed the same results. It is clearly evident from Western blot data that QC can 
trap FACT in chromatin in vitro. However, the in vivo finding is not quite obvious when 
using QC alone. As shown here, QC treatment leads to mild decrease of SSRP1 in the 
nucleus. The effect of chromatin trapping is very clear in the combination group, which 




FACT is overexpressed in colon cancer tissue and cell lines  
Previously, we showed that primary tumor tissues of CRC and other types of 
cancer patients have higher AcAPE1 levels compared to adjacent-non-tumor tissues 
(44,108). Recent reports demonstrate that FACT expression is strongly associated with 
poorly differentiated cancers and low overall survival (97,103,104,106). Here we examined 
the levels of SSRP1 and AcAPE1 in CRC patients’ tumor tissues. Both subunits of FACT 
complex and AcAPE1 were overexpressed in tumor but not in adjacent normal tissues 
(Fig. 45). This finding was confirmed in various colon cancer cell lines using HCEC cells 
for comparison (Fig. 46). These data indicate a potential role of overexpression of FACT 
and AcAPE1 in inducing chemoresistance.  
 
 
Figure 45. Expression of FACT complex and AcAPE1 is elevated in colon cancer 
tissues.  
To investigate the expression levels of AcAPE1 and FACT complex in human colon cancer, 
we used colon cancer samples and performed western blot analysis. (Left) Levels of APE1, 
AcAPE1, SSRP1 and SPT16 were elevated in tumor (T) as compared to the adjacent 
normal (N) tissue extracts of CRC patients. (Right) The expression level of each protein 
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in tumor was presented in fold change compared to normal adjacent tissues. Data were 
expressed as mean ± SEM of three independent experiments. MANOVA with Tukey's 
HSD test, ** p<0.01, **** p<0.0001. 
 
 
Figure 46. Expression of FACT complex and AcAPE1 is elevated in multiple colon 
cancer cell lines.  
After we demonstrated that the human colon cancer samples had higher levels of AcAPE1 
and FACT complex, we sought to determine the expression levels in most commonly used 
colon cancer cells lines, including RKO, HCT116, SW620, GEO, and LoVo. (Left) The 
levels of AcAPE1, SSRP1, and SPT16 were elevated in various colon cancer cell lines as 
compared to normal colon cell line HCEC. (Right) Bar graph showing elevated levels of 
SPT16, SSRP1 and AcAPE1 in multiple CRC cell lines compared to normal HCEC cells. 
Expression levels were presented in fold change with respect to normal HCEC cells. Data 
were expressed as mean ± SEM of three independent experiments. One-way ANOVA 




FACT (SSRP1) expression and AcAPE1 levels positively correlate with 
chemoresistance in CRC patients  
To determine the clinical significance of elevated levels of FACT and AcAPE1 in 
CRC, we extended our analyses by assessing SSRP1 and AcAPE1 levels in 39 CRC 
patients at different T stages. Among them, 19 patients had a moderate response and the 
other 20 had no response or minimal response to chemotherapy. Four (10.3%) were 
characterized as microsatellite instable or MMR deficient. This is consistent with prior 
reports that sporadic, noninherited dMMR CRC constitutes 10-15% of all CRCs (109). The 
percentages of positive cells and the staining intensity of SSRP1 and AcAPE1 level were 
significantly higher in CRC tumor tissue compared to control (Fig. 47). Although SSRP1 
or AcAPE1 staining varied among the samples within a particular stage of CRC, we found 
a significant increase in percentage of positive SSRP1 and AcAPE1 staining cells from 
stage T2 to T4, indicating that SSRP1 and AcAPE1 level increases with tumor depth 
invasion (Fig. 48). Analysis of staining intensity of AcAPE1 and SSRP1 in tumor samples 
(characterized as low, medium and high intensity) revealed higher numbers of positive 
cells exhibiting high intensity staining with increasing tumor stage (Fig. 49).  
Next, we determined the relationship between FACT expression and acetylation 
of APE1 across all patient’s samples. We revealed a moderate but significantly positive 
correlation between SSRP1 and AcAPE1 levels in CRC samples (Fig. 50). We found that 
patients exhibiting no or minimal response to 5-FU had distinct staining patterns compared 
to patients exhibiting moderate responses (Fig. 51). Quantitation of the percentage of 
positive staining cells showed that the percentage of positive SSRP1 or AcAPE1 was two-
fold higher in non- or minimal responders compared to moderate responders (Fig. 52). 
Additionally, three out of four patients who have loss of MSH2 and MSH6 were found to 
have minimal or no response and they had high levels of AcAPE1 and FACT (Fig. 53). 
75 
 
Overall, these data indicate that the expression levels of SSRP1 and AcAPE1 positively 
correlates with 5-FU resistance in CRC patients. 
 
 
Figure 47. AcAPE1 and SSRP1 expression increases in tumors of higher T stage.  
To investigate the prognostic value of AcAPE1 and SSRP1 in colon cancer, we first 
collected invasive colon cancer samples (T2 or above). These patients received 
chemotherapy before surgery and underwent surgery to remove residual tumor. We 
performed IHC staining of AcAPE1 and SSRP1. A total of 39 CRC patients with different 
T stages were included. Note that T stage pertains to tumor invasion depth. T2 means 
tumor invading muscularis propria, and T3 means tumor invading through muscularis 
propria into subserosa or nonperitonealized pericolic or perirectal tissues. T4 indicates 
that tumor directly invades other organs or structures and/or perforates visceral 
peritoneum. Normal colon tissue was used as control. Grossly we noted that the staining 
intensity and percentage of cells with positive staining increased as tumor invasion depth 





Figure 48. Percentage of AcAPE1 and SSRP1 positive staining cells increases as 
tumor progresses in terms of invasion depth.  
To quantify the staining result, the percentage of positive staining cells and staining 
intensity (next figure) were analyzed by Definiens Releases Tissue Studio® 4.3 which is 
available at the UNMC Tissue Science core facility. The percentage of cells positive for 
AcAPE1 (Left) or SSRP1 (Right) from ten random high field in each sample was pooled 
and average for each sample was plotted. The percentage of AcAPE1 and SSRP1 positive 
staining increases as tumor invasion increases. Kruskal-Wallis test with Games-Howell 





Figure 49. Tumors of higher stage demonstrate higher portion of cells with high 
intensity.  
We further characterized the staining intensity of the IHC sections. The staining intensity 
was analyzed by Definiens Releases Tissue Studio® 4.3. We used a stain deconvolution 
algorithm to separate the DAB chromogen stain and the hematoxylin counterstain in all 
tissue cores. We then measured the brown chromogen intensity across all tissues to 
obtain the range of pixel density. Based on the range, we divided the staining intensity into 
3 categories using one third threshold increment in the range. The percentage of cells with 
low, medium and high staining intensity in each group for AcAPE1 (Left) and SSRP1 (Right) 
was analyzed and plotted. We found that higher numbers of positive cells exhibiting high 
intensity staining of AcAPE1 and SSRP1 with increasing tumor stage. Kruskal-Wallis test 





Figure 50. The AcAPE1 and SSRP1 expression is correlated in colon cancer.  
As AcAPE1 is overexpressed in colon cancer, and FACT complex facilitates its function, 
we examined whether the expression of these two proteins was correlated. Percentage of 
AcAPE1 and SSRP1 positive cells in each sample were plotted and linear regression was 
performed which demonstrated that the expression of AcAPE1 was correlated with SSRP1 





Figure 51. Minimal or none responders have significantly higher percentage of 
AcAPE1 and SSRP1 staining.  
As all the tumor samples we included in this study were from patients with invasive cancer, 
and the fact that all invasive cancer received neoadjuvant chemotherapy, they 
represented ideal post-treatment samples for analyzing the tumor after chemotherapy 
drugs. We divided the samples into two groups, moderate responder (n=19) vs 
none/minimal responder (n=20). Treatment response is assessed by clinician using 
modified Ryan Tumor Regression Grading System. We found that none/minimal 
responders had strong staining of AcAPE1 and SSRP1. The IHC staining was then 




Figure 52. Minimal or none responders have significantly higher percentage of 
AcAPE1 and SSRP1 staining.  
The percentages of cells with positive AcAPE1 and SSRP1 staining were compared 
between moderate and minimal/none response groups. Similarly, we used Definiens 
Releases Tissue Studio® 4.3 to quantify the percentage of positive staining of AcAPE1 
and SSRP1 in 10 random high power field images. We found that compared to moderate 
responders, none/minimal responders had significantly higher percentage of AcAPE1 and 
SSRP1 staining. Together these data suggest that AcAPE1 and SSRP1 is elevated in 
colon cancer, and the expression is correlated. The none/minimal responders have higher 
percentage of positive staining for both proteins, indicating a potential role of 
chemoresistance derived from the overexpression of AcAPE1 of which the activity is 
enhanced by concurrent overexpression of SSRP1. The finding is consistent with our in 
vitro and in vivo study that targeting AcAPE1 and FACT complex may represent a novel 





Figure 53. Illustration of MMR deficient patient in our cohort and their staining of 
AcAPE1 and SSRP1.  
Among all 39 CRC patients, 4 were previously identified as MMR deficient. 75% of them 
(3 out of 4) had minimal or none response to neoadjuvant chemotherapy (details of 
therapy regimens was not provided), and IHC staining revealed that these patients had 
high percentage of positive staining for AcAPE1 and SSRP1. Stacked column chart 
showed staining intensity characterization of positive staining cells. Note that a higher 
portion of the positive staining was characterized as high intensity in minimal or none 
response patients. The post-therapy pathologic stages (T=primary tumor, N=lymph node, 








Resistance to 5-FU remains a major challenge in the treatment of dMMR CRC. 
Several mechanisms are believed to be responsible for 5-FU resistance, including 
overexpression of TS enzyme due to gene amplification, deficient MMR pathway and 
enhanced DNA damage repair resulting in reduced apoptosis (70,110). However, TS 
levels cannot explain the therapeutic resistance to 5-FU in dMMR-CRC (111), and several 
clinical studies have shown that defective mismatch repair is a strong predictor for lack of 
response of 5-FU-based adjuvant therapy in dMMR CRC (109,112,113). This study 
reveals a novel mechanism of histone chaperone FACT complex in inducing 5-FU 
resistance in dMMR CRC. Our data show that FACT facilitates the recruitment and 
acetylation APE1 to the damage sites, and promotes repair of 5-FU-induced DNA 
damages via BER pathway. Additionally, we demonstrate extensively that targeting FACT 
with small molecules curaxins significantly improve the efficacy of 5-FU in dMMR CRC 
both in vivo and in vitro. We found a strong clinical correlation between FACT or AcAPE1 
levels with CRC patient’s response to chemotherapy. Therefore, FACT complex is a 
promising target to increase 5-FU treatment response, and our study provides a 
compelling rationale to combine CBL0137 with 5-FU to provide synergistic effects to 
overcome the 5-FU resistance in dMMR CRC.  
Overexpression of APE1 in various cancer types including colon, lung and breast 
and its association with chemotherapeutic resistance as well as patients' poor prognosis 
are well documented (2,43,114). AP site or SSB is a common intermediate in the BER 
pathway that is generated after treatment with many chemotherapeutic drugs including 5-
FU and alkylating agents (2). The repair of AP sites/SSBs by APE1 on naked DNA or 
nucleosomal DNA substrate has been extensively investigated in vitro (115,116), 
however, till to date, how APE1 repair AP sites in the context of the nucleosome in 
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chromatin remains largely unknown. Earlier, we discovered that human APE1 could be 
acetylated (AcAPE1) at multiple lysine (Lys 6, 7, 27, 31, 32 & 35) residues in the N-terminal 
domain by p300 (38,117). Acetylation of these Lys residues modulates both DNA damage 
repair function of APE1 and the expression of multiple genes (26,35,38,44,84,117,118). 
We have recently shown that acetylation of APE1 occurs at AP sites damage in chromatin 
which enhances the AP-endonuclease activity of APE1 (38). Furthermore, we 
demonstrated that primary tumor tissues of diverse origins have higher levels of acetylated 
APE1 and absence of APE1 acetylation sensitizes cells to many chemotherapeutic agents 
(44). In this study, we discover that APE1 interacts with FACT complex and induction of 
DNA damages with 5-FU enhances their recruitment and colocalization at damage sites 
in chromatin. FACT complex, as a histone chaperone, facilitates the removal and deposit 
of histone H2A/H2B in nucleosome at the promoter, which in turn stimulating the formation 
of the preinitiation complex, and at the coding sequence for RNA pol II elongation (93,119). 
Increasing evidence suggests that FACT plays a role in DNA damage repair in evicting 
and depositing H2A and H2B, at sites of UV damage and single-stand breaks in DNA 
(91,92). Our results, using multiple approaches, show that FACT facilitates the access 
and subsequent acetylation of APE1 to the damage sites and promotes efficient repair of 
5-FU-induced DNA damages. (1) Our ChIP assays show that downregulation of FACT 
complex significantly reduced the occupancy of AcAPE1 to the p21 and DTL promoter 
regions upon induction of DNA damages. (2) Our biochemical and confocal SIM data show 
that FACT knockdown reduced APE1 acetylation levels. As acetylation of APE1 occurs 
after binding to AP sites in chromatin, this data indicates that absence of FACT complex 
significantly reduced binding of APE1 at damage sites in chromatin. (3) Our FRAP data 
show that absence of FACT significantly reduces the mobility of GFP-tagged APE1 in 
chromatin upon induced DNA damages. (4) Depletion of endogenous FACT complex 
significantly delays the repair of MMS-induced damages and results in accumulation of 
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AP sites/SSBs in the genome compared to control cells. (5) CRC cells are unable to repair 
5-FU induced SSBs in the absence of FACT or in the presence of FACT inhibitor 
CBL0137. Thus multiple lines of compelling evidence establish a key role of the histone 
chaperone FACT in the repair of AP site damage in chromatin and FACT complex as a 
novel regulator of BER pathway. It is likely that at the initiating steps of repair, DNA 
glycosylase responsible for removing the incorporated 5-FU facilitates recruitment of 
FACT to sites of damage through physical interaction. Consistent with this, SSRP1 was 
shown to interact with DNA glycosylase (120). We predict that FACT remains at damage 
sites and might cooperate to facilitate complete repair by promoting chromatin relaxation 
and subsequent recruitment of downstream repair protein APE1 and XRCC1 through 
physical interaction (92). Consistently, a recent study shows that SSRP1 cooperates with 
PARP1 and XRCC1 to facilitate SSBs repair by chromatin priming (92). This may also 
facilitate the recruitment of histone acetyltransferase p300 to acetylate APE1 and 
acetylation in turn enhances the endonuclease activity of APE1 and promotes faster 
repair. Our current study establishes a key role of FACT complex in BER pathway via 
regulating APE1 activity which contributes to drug resistance. 
Earlier study showed that downregulation of UNG or SMUG 1 responsible for 
removing 5-FU from DNA did not enhance the 5-FU sensitivity in murine cells (121). This 
observation can be explained by the fact that the enzymes removing 5-FU from DNA are 
functionally redundant, the loss of one of these enzyme would not affect the sensitivity. 
On the other hand, AP site or SSB, a common intermediate in the BER pathway that are 
generated after removal of incorporated 5-FU, are primarily repaired by APE1. Indeed, our 
data show that downregulation of APE1 significantly sensitizes a panel of 5-FU resistant 
CRC cells in vitro. In the absence of MMR pathway, APE1-dependent BER is primarily 
responsible for removing 5-FU from DNA in dMMR-CRC cells and higher levels of APE1 
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and FACT would promote 5-FU resistance. Thus, targeting APE1 or FACT represents an 
opportunity for sensitizing dMMR CRC to 5-FU. However, in the absence of any selective 
and nontoxic small molecules inhibitor of APE1, we propose that CBL0137, an inhibitor of 
FACT, could be used for sensitizing dMMR CRC patients to 5-FU. Our data show that in 
the presence of CBL0137, cells were unable to repair the 5-FU-induced DNA breaks and 
the addition of CBL0137 sensitizes 5-FU resistant dMMR CRC cell lines in vitro. 
Importantly, we demonstrate that this therapeutic strategy is also effective in vivo. Our 
data show that while treatment with 5-FU alone or CBL0137 alone had minimal effects, 
combination of CBL0137 (or the first generation drug QC) and 5-FU significantly reduced 
tumor growth in vivo. These data reveal that curaxin helps overcome 5-FU resistance in 
dMMR CRC. The second generation curaxin CBL0137 is in the final stage of multi-center 
phase I clinical trial for metastatic or unresectable advanced solid malignancies 
(NCT01905228), and it has not yet exhibited dose-limiting toxicity. It modulates several 
important signaling pathways through inhibition of FACT function (103,104,122-124). 
Increasing evidence suggests that CBL0137 itself has very less cytotoxic effect 
(102,106,125). Our data also support that combination of CBL0137 with 5-FU has no 
major toxicity in vital organs in mice. Our studies and others have identified curaxins as a 
new class of drugs that can be used to sensitize cells to many chemotherapeutic agents 
(102,106). The mechanism of action is fundamentally different from current 
chemotherapeutic drugs. By binding DNA within chromatin and altering FACT activities, 
curaxins can modulate multiple DNA damage repair pathways to sensitizes cells to 5-FU. 
Studies have shown that curaxins do not cause DNA damage and affect general 
transcription and are therefore expected to be well tolerated, as we have shown in mice 
experiments. We propose that combination of CBL0137 has several advantages, including 
extremely efficient in reaching nuclear DNA as they are not substrate for multidrug 
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transporters, and high DNA affinity that facilitates binding to bent nucleosome without 
causing DNA damage.  
Although our data show that combination of CBL0137 with 5-FU provides better 
control of xenograft growth in vivo, we cannot eliminate the possibility that curaxins also 
affect the expression of other genes involved in modulating the tumor growth or sensitivity 
to 5-FU. FACT inhibitor CBL0137 has been shown to synergize with cisplatin in small cell 
lung cancer by increasing Notch signaling and targeting tumor initiating cells (126). It has 
been shown that curaxins simultaneously suppress NF-κB and activates p53 (106). 
Targeting FACT with CB0137 has also been shown to eliminate glioblastoma stem cells 
and prolong survival in a preclinical model (103). Nonetheless, here we add to the current 
knowledge by providing compelling evidence that curaxins exhibit strong synergy with 5-
FU by interference of BER pathway. We showed that AcAPE1 and SSRP1 levels were 
elevated in colon cancer samples and could serve as a predictor for CRC patients’ 
response to 5-FU. Patients with minimal or none response demonstrated a distinct 
expression profile as compared to those with moderate response. However, the use of 
AcAPE1 and SSRP1 levels as a predictor for treatment response requires a larger number 
of patient samples and ideally should be tested prospectively. We identified four patients 
(10.3%) with MMR deficiency and found three of them had minimal or none response to 
5-FU-based chemotherapy. These patients have high levels of AcAPE1 and FACT which 
is consistent with our in vitro and animal studies. Because of the rarity of sporadic dMMR 
CRC and Lynch syndrome in nature, we are in the process of collecting more clinical 
samples prospectively to validate our results and would propose that further analysis at a 
larger population basis is necessary to safely draw the conclusion that FACT can be 
targeted for chemosensitization in dMMR CRCs.  
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In conclusion, our study has identified a novel role of FACT complex in BER 
pathway, and advanced the understanding on how nucleosome remodeling FACT 
complex contributes to 5-FU resistance in CRC via promoting DNA damage repair. Our 
study reveals that targeting FACT by combining CBL0137 with 5-FU is a promising 




CHAPTER 2. TARGETING FACT COMPLEX INTERFERES DNA DAMAGE REPAIR 
AND TRANSCRIPTION AND SENSITIZES MEDULLOBLASTOMA TO 
CHEMOTHERAPY AND RADIATION  
 
Introduction  
Medulloblastoma (MB) is the most common malignant brain tumor in childhood, 
accounting for nearly 20-25% of all pediatric brain tumors (127,128). Genetically, MB is a 
heterogeneous tumor that consists of four molecular subtypes: Wingless (WNT), Sonic 
Hedgehog (SHH), Groups 3 and Group 4 (129,130). A multimodal approach that consists 
of surgical resection, preceded or followed by craniospinal radiation and cisplatin-based 
chemotherapy, is the standard of care (131-134). High doses of chemotherapy and 
radiation cause delayed complications that result in debilitating cognitive, neurologic, and 
endocrinologic sequelae which severely impacts the quality of life of pediatric cancer 
survivors (135-138). Additionally, overall survival rate is still poor despite the cure rates 
are improving in 75% of patients (139). Research efforts directing at reducing treatment 
toxicity while remaining high cure rate is of importance. 
Chemotherapeutic drugs and radiation therapy act, in part, by generating DNA 
damages in proliferating tumor cells. Apurinic/apyrimidinic (AP) sites are one of the most 
common types of DNA damage that occur following treatments (140). Both radiation and 
chemotherapeutic drug cisplatin exert their cytotoxic effects by directly inducing DNA 
damages in cells. Cisplatin induces intrastrand and interstrand crosslinks (ICLs) in DNA 
which are primarily repaired by nucleotide excision repair (NER) pathway (141,142). On 
the other hand, radiation induces isolated DNA lesions including AP sites and single-
strand breaks (SSBs) and double-strand breaks (DSBs) (143,144). The multifunctional 
DNA repair enzyme AP-endonuclease (APE1) initiates the repair of AP sites and SSBs, 
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which constitute ~65% of the DNA damage caused by radiotherapy via the base excision 
repair (BER) pathway (145). Previous report has demonstrated that APE1 is 
overexpressed and its activity is associated with response to radiation and chemotherapy 
in MB. Recent evidence has also demonstrated the role of BER pathway (146-148), where 
targeting BER showed enhanced sensitivity to cisplatin (149). Altered or efficient repair of 
DNA damages could play a major role in chemotherapy resistance (150). The 
mechanisms of repair of AP sites or SSBs and cisplatin-induced DNA cross-link damages 
via BER and NER have been extensively investigated in naked DNA in vitro. However, 
how these damages are repaired in the context of nucleosome in chromatin in cells and 
whether these repair pathways can be targeted to increase the efficacy of chemo and 
radiation therapy in MB remain an open question.  
DNA in the eukaryotic cell is packaged into nucleosome in chromatin.  Thus cells 
must repair DNA lesions including AP sites or SSBs within the context of nucleosome in 
chromatin. Facilitates chromatin transcription (FACT) complex is a nucleosome 
remodeling protein complex that has histone chaperone activity and facilitates 
transcription through chromatin. The FACT complex, a heterodimer of Structure-Specific 
Recognition Protein1 (SSRP1) and Suppressor of Ty (SPT16) (151), was originally 
identified as a histone chaperone complex that facilitates the removal and deposition of 
histone H2A/H2B in nucleosomes during transcription initiation and elongation (63,93). 
Furthermore, increasing evidence suggests that the FACT complex plays a role at sites of 
UV damage and single-strand breaks (SSB) in cells (91,92). SSRP1 is recruited to SSB 
in PARP-dependent manner and retained at DNA damage sites by N-terminal interactions 
with the DNA repair protein XRCC1 (152). On the other hand, SPT16 is found to accelerate 
the exchange of H2A/H2B at sites of UV-induced DNA damage and is involved in NER 
pathway (64). Curaxins, a class of small molecule drugs with broad anticancer activity, 
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destabilize nucleosomes and inhibits FACT in chromatin (102,125). The second 
generation curaxin CBL0137, has been utilized in phase II clinical trial for metastatic or 
unresectable advanced solid malignancies, modulates several important pathways 
through inhibition of FACT function.  
In this study, we seek to investigate whether FACT interacts with APE1 and 
functional cooperation between FACT and APE1 induces radiation and cisplatin 
resistance in MB, and whether targeting FACT with curaxin can sensitize MB to cisplatin 
and radiation. Our study show that FACT complex interacts with APE1 and FACT 
facilitates repair of radiation and cisplatin-induced DNA in BER pathway via promoting the 
recruitment and acetylation of APE1 (AcAPE1) to damage sites in chromatin. We show 
that primary tumor tissues of MB patients have higher FACT and AcAPE1 levels. Targeting 
FACT complex with Curaxin/CBL0137, inhibits DNA repair and alters gene expression. 
Curaxin/CBL0137 significantly improves efficacy of cisplatin in MB in vitro and in vivo 
xenograft models. Together, our study unveils a novel role of FACT complex in promoting 
radiation and cisplatin resistance in MB, and demonstrate that FACT inhibitor 
curaxins/CBL0137 can be used as a radiation and chemotherapy sensitizer to augment 
treatment efficacy and reduce the treatment toxicity in MB patients.  
 
Materials and methods: 
Cell culture, plasmids, siRNAs, transfection and treatments 
HD-MB03 and UW228 cells were grown in RPMI 1640 Medium (ATCC 
modification) (Gibco) supplemented with 10% fetal calf serum (FCS; Sigma) and antibiotic 
mixture of 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco). ONS-76 cells were 
cultured in RPMI 1640 Medium (ATCC modification) (Gibco) supplemented with 10% fetal 
calf serum (FCS; Sigma), antibiotic mixture of 100 U/ml penicillin and 100 µg/ml 
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streptomycin with 2 mL-Glutamine (Gibco). DAOY, D283 and SVG p12 cells were grown 
in Eagle's Minimum Essential Medium (Gibco) supplemented with 10% fetal calf serum 
(FCS; Sigma) and antibiotic mixture of 100 U/ml penicillin and 100 µg/ml streptomycin 
(Gibco). All cell lines were kindly provided by Dr. Sutapa Ray (Division of Pediatric Cancer 
Research Group at UNMC) and authenticated using STR DNA profiling by Genetica DNA 
laboratories (Burlington, NC) two years ago before being used in this study.  
Western Blot Analysis 
Cell fractionation was performed as described previously (81). Whole cell lysates 
or cell fractions were resolved on 10 to 12.5 % SDS-PAGE gel and transferred to nylon 
membranes for blotting. Primary antibodies were used including SPT16 (Abcam, 204343), 
SSRP1 (Biolegend, 609702), α-HSC70 (B6-Sc7298, Santa Cruz Biotechnology), H2A 
(Abcam, 26350), GAPDH( CST, 8884s), APE1 (Novus Biologicals, NB100-116), α-tubulin 
(Abcam, 52666) and AcAPE1 (35,84). Immunoblot signals were detected using Super 
Signal West pico chemiluminescent substrate (Thermo Scientific) after treating with HRP-
conjugated secondary Ab (GE Healthcare). 
Patient tissue samples and analysis 
Tissues were collected in accordance with institution's review board approval and 
informed consent was waived. 12 of the Medulloblastoma cancer samples were obtained 
from tissue bank at UNMC. 59 of the deidentified Medulloblastoma cancer patients’ 
samples were obtained from Department of Pathology of Sun Yat-sen University Cancer 
Center. The deparaffinized sections were stained per standard IHC protocol. The 
antibodies used were: AcAPE1 (1:200) and SSRP1 (1:100). Staining percentage of 
positive cells were analyzed by Definiens Releases Tissue Studio® 4.3. The data were 
plotted using GraphPad Prism 7.  
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Immunoprecipitation (IP)  
Whole cell extracts of HD-MB03 or ONS-76 cells were pre-cleared with protein A/G 
Plus agarose beads and IP was performed with AcAPE1 antibody or control IgG (Santa 
Cruz, sc-2003). The whole cell extracts of control and IR-treated cells were 
immunoprecipitated with the same antibody. The immunoprecipitated proteins were 
resolved in SDS-PAGE and identified by Western Blot analysis with the indicated 
antibodies.  
Immunofluorescence 
Cells grown on coverslips were fixed with 4% formaldehyde (Sigma-Aldrich) and 
stained with immunofluorescence as described previously (38). Primary antibodies used 
were mouse monoclonal anti-APE1 (1:100; Novus Biologicals, NB100-116), anti-AcAPE1 
(1:50; Ref. 27, 31,32), SSRP1, SPT16 (1:50; Abcam, 204343). Images were acquired by 
use of a fluorescence microscope with a 63× oil immersion lens (LSM 510; Zeiss), and 
structured illumination microscopy (SIM) was done with an Elyra PS.1 microscope (Carl 
Zeiss) by using a 63× objective with a numerical aperture of 1.4. ImageJ software was 
used to measure Manders colocalization using the JaCoP plug-in. 
Chromatin Immunoprecipitation (ChIP) Assay 
ChIP assay was performed after double crosslinking of cells with disuccinimidyl 
glutarate and formaldehyde, with protein A/G Plus agarose beads (Santa Cruz, sc-2003) 
using with AcAPE1 and control IgG (Santa Cruz) following the procedure as described 
earlier (38,84). The immunoprecipitated purified DNA was used to amplify the p21 and 
DTL promoter regions using SYBR GREEN-based (Thermo Scientific) Real Time PCR 
analysis. The following primers are used: p21 forward 5’-CAGGCTGTGGCTCTGATTGG-
3’, reverse 5’-TTCAGAGTAACAGGCTAAGG-3’; DTL forward 5’-
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TCCTGCAAATTTCCCGCAAC-3’, reverse 5’- GGCTATGGCGAACAGGAACT-3’. Data 
were represented as relative enrichment with respect to IgG control based on 2−ΔCT 
method. 
Cell Viability Assay 
Cell viability was evaluated by MTT assay per standard protocol. The IC50 values 
were calculated using GraphPad Prism 7 (GraphPad Software Inc., San Diego, CA). 
Single Cell Gel Electrophoresis (Alkaline comet assay) 
Comet assay was performed following the manufacturer’s protocol (Trevigen, # 
4250-050-K). At least three independent experiments were performed for each condition. 
Tail moment was quantitated at least in 50 independent cells for each condition using the 
OpenComet v1.3.1 software. 
Xenograft studies 
All animal experiments were performed following the approval of Institutional 
Animal care and use committee (IACUC). HD-MB03 and ONS-76 cells (1×106 in 100 μl 
medium) were injected subcutaneously over the left and right flanks in athymic nude mice 
(Charles Rivers, Wilmington, MA). Subcutaneous tumors were allowed to grow for 1-2 
weeks before treatments. When tumor volume reached 100 mm3, the mice were divided 
into four treatment groups (each groups n=5 mice) and received treatments every other 
day for four weeks. The following drugs: cisplatin 2 mg/kg, CBL0137 30 mg/kg were 
injected intraperitoneally. Combination group received both cisplatin and CBL0137. 100 
μL PBS was given to control group. Body weight and tumors volume were measured 
before each treatment. The mice were euthanized after the end of treatment cycles. 
Xenograft tumor was fixed in formalin and paraffin-embedded tissue sections were used 
to perform IHC staining AcAPE1, Ki67 (1:500, CST, 9027), SSRP1, PARP1(1:100, Santa 
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Cruz, sc-8007), and Caspase 3(1:100, Santa Cruz, sc-7272). Statistical analyses and 
comparisons of tumor growth was calculated using ANOVA (GraphPad Prism 7). The 
percentage of positive staining was quantified with 10 random high-power field images 
using TMARKER (88). Additive or synergistic effect was examined using online tool 
SynergyFinder (https://synergyfinder.fimm.fi) (89). 
Terminal dUTP nick-end labeling (TUNEL) assay  
Xenograft tumor sections (4 μm thick) were deparaffinized, re-hydrated and 
submitted to apoptosis quantification analysis according to manufacturer’s protocol 
(Abcam, ab206386).  
Statistical analysis 
Results are shown as the mean ± SEM of three independent experiments. Shapiro-
Wilk test was used to test for normality distribution. If the Sig. value of the Shapiro-Wilk 
Test is greater than 0.05, the data is considered normal. For comparison among multiple 
groups, one-way analysis of variance (ANOVA) followed by Dunnett's post-hoc test or 
Tukey's HSD test was used depending on the nature of comparison. When there were 
more than one continuous dependent variables, one-way multivariate analysis of variance 
(one-way MANOVA) was used to determine whether there were any differences between 
independent groups. If data did not distribute normally, Kruskal-Wallis test followed by 
Games-Howell post-hoc test was used as a non-parametric counterpart of ANOVA for 
multiple comparison. Statistical analyses were performed in SPSS v22.0 (IBM SPSS 
Statistics). A p-value of less than 0.05 is considered statistically significant. * p<0.05, ** 





AcAPE1 and SSRP1 levels are elevated in medulloblastoma and associated with 
overall patients’ survival 
We have shown that APE1 is acetylated (AcAPE1) at AP site damage in chromatin 
by p300 and increased level of AcAPE1 in tumor cells promotes resistance to many 
chemotherapeutic agents (38,44). We examined the AcAPE1 and SSRP1 levels in a 
cohort of 71 MB patients’ tissue specimens by IHC staining. Among these patient’s, there 
were 44 children and 27 adults; clinicopathological characteristics of the cohort are shown 
in Table 1. We found that AcAPE1 and SSRP1 were significantly elevated in MB tissues 
compared to adjacent normal tissues (Fig. 54). Across all histology types, the percentage 
of positive cells of AcAPE1 and SSRP1 was significantly higher than normal adjacent 
tissues (Fig. 55). There was no statistical difference between classical and 
Desmoplastic/Nodular (D/N) groups. However, large cell/anaplastic (LCA) group 
demonstrated significantly higher percentage of positive staining cells as compared to 
other histology types and normal adjacent tissues. Furthermore, a positive correlation 
between AcAPE1 and SSRP1 levels (r=0.57, p<0.0001, Fig. 56) was observed. Kaplan-
Meier survival analysis was used to compare the overall survival in patients with high and 
low AcAPE1 and SSRP1 levels. Results show that elevated expression of AcAPE1 and 
SSRP1 was associated with worse overall survival (Fig. 57). We tested this in a larger 
database, R2 Genomics (153). Consistent with our result, analysis of the database of 763 
MB patients’ mRNA expression profiles reveals a correlation between expression levels 
of APE1 or SSRP1 and the overall survival of these patients (Fig. 58). Together, these 
data suggest that APE1 and FACT are overexpressed in MB and levels of AcAPE1 and 





Figure 54. Overexpression of AcAPE1 and SSRP1 is observed in MB.  
To investigate if AcAPE1 and SSRP1 may play a role in the treatment response and 
prognosis of MB, samples from medulloblastoma were submitted for IHC analysis. MB 
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can be divided into four different groups based on their histology: classical, 
desmoplastic/nodular (D/N), medulloblastoma extensive nodular (MBEN) and large 
cell/anaplasia (LCA). Overexpression of AcAPE1 and SSRP1 was observed in MB across 
all histology groups. 
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Figure 55. MB tissues have higher percentage of AcAPE1 and SSRP1 positive 
staining as compared to normal tissues.  
The percentage of cells positive for AcAPE1 or SSRP1 from ten random high field in each 
sample was pooled. We found that all histology groups had higher percentage of positive 
staining of AcAPE1 and SSRP1. While the statistical difference was noted when 
comparing LCA group with other groups, caution must be taken when interpreting the 
result given the relatively small number of cases included. This is due to the rarity of MB 
in general population and majority is classical type. Additionally, unlike other solid tumor 
in human, the resection of brain tumor does not always include significant amount of 
surrounding normal tissue as this will cause devastating neurological consequences. 
Therefore, we were only able to include seven normal adjacent tissues for comparison. 






Figure 56. The expression of AcAPE1 and SSRP1 is correlated in MB.  
Based on the quantification of IHC staining result, we analyzed the association between 
AcAPE1 and SSRP1 expression using linear regression. We found that the expression of 
AcAPE1 was correlated with SSRP1 with Pearson r of 0.57. This provides rationale for the 







Figure 57. Survival analysis based on AcAPE1 and SSRP1 expression.  
To investigate whether AcAPE1 and SSRP1 plays a role in the prognosis of MB patients, 
we performed Kaplan-Meier analysis to analyze the overall survival in relation to AcAPE1 
and SSRP1 expression. We calculated the median of the percentage of positive staining 
cells and divided the cohort into two groups (high vs low expression). A total of 44 pediatric 
patients in our cohort were included. We found that high expression of AcAPE1 and 
SSRP1 was associated with poor overall survival. The p value is statistically significant in 
AcAPE1 but not in SSRP1. The high SSRP1 group did demonstrate worse overall survival. 
A possible explanation is the small number of samples available for analysis makes it 
difficult to detect statistical difference. Therefore, we sought to examine the prognostic 






Figure 58. Survival analysis using R2 genomics demonstrates that high expression 
levels of AcAPE1 and SSRP1 is correlated with poor overall survival.  
As our cohort was relatively small, we extended our survival analysis using R2 Genomics. 
This is a freely accessible online genomics analysis and visualization tool which can 
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analyze a large collection of public data. In this database, there is a cohort of 612 MB 
patients that have survival and gene expression data available for analysis. We analyzed 
the prognostic significance of APE1 (aka. APEX1, Top) and SSRP1 (Bottom) gene 
expression by Kaplan-Meier plot and found that the expression levels of APE1 and SSRP1 
were associated with poor overall survival. Together, these data suggest that the AcAPE1 
and SSRP1 is overexpressed in MB, and their elevated expression plays a role in the 
prognosis. 
 
AcAPE1 interacts with FACT complex and radiation enhances their colocalization  
We used multiple MB cells line along with fetal glial cell line SVG p12 as normal 
control to determine the expression levels of FACT complex and APE1. As shown in Fig. 
59, both subunits of FACT complex, SSRP1 and SPT16 were upregulated in MB cells 
lines. Concurrently, AcAPE1 showed overexpression in these tumor cell lines while the 
total APE1 had no change in expression. The quantification of WB result was shown in 
Fig. 59. As both FACT and AcAPE1 are elevated in MB and one recent study has shown 
that FACT complex is involved in DNA SSBs damage repair, we examined whether 
AcAPE1 interacts with FACT complex in MB cell lines. We immunoprecipitated (IP) 
endogenous AcAPE1 from HD-MB03 and ONS-76 cell extracts and examined the 
presence of FACT complex in AcAPE1 IP by Western blot analysis. We found both 
subunits of FACT in AcAPE1 IPs (Fig. 60). Confocal microscopy revealed colocalization 
of AcAPE1 with SPT16 and SSRP1 in the nucleus of MB cells (Fig. 61). To determine 
whether radiation therapy which induces SSBs and AP sites damages in the genome 
promotes interaction of AcAPE1 and FACT at damage sites, we exposed HD-MB03 cells 
to radiation. Our Co-IP data showed that there was an increasing association of AcAPE1 
and FACT complex upon induction of DNA damage with radiation (Fig. 62). Confocal 
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microscopy revealed enhanced colocalization of both subunits of FACT complex with 




Figure 59. Elevated expression of AcAPE1 and FACT complex is observed in 
various MB cell lines.  
We sought to determine the expression levels of both proteins in MB cell lines. The 
expression levels of SPT16, SSRP1, AcAPE1 and APE1 were determined using Western 
blotting in multiple MB cells lines. ONS-76, DAOY and UW228 are from Sonic-Hedgehog 
(SHH) group, HD-MB03 and D283 are from group 3. The expression levels of proteins 
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were semi-quantified using ImageJ. GAPDH was used as control. Compared to SVG p12 
cells which were used as normal glial cell control, MB cells demonstrated significantly 
higher expression of AcAPE1 and SSRP1. Three biological replicates were performed. 
Results are shown as the mean ± SEM. One-way ANOVA with Tukey's HSD test, * p<0.05, 
** p<0.01, *** p<0.001, **** p<0.0001. 
 
 
Figure 60. AcAPE1 is associated with FACT complex.  
To investigate whether AcAPE1 interacts or associated with FACT complex, co-
immunoprecipitation using AcAPE1 antibody was performed using HD-MB03 and ONS-
76 cell extracts. ONS-76 and HD-MB03 are p53 WT cell lines. DAOY and UW228 have 
p53 mutations. IgG was used as negative control. We found that AcAPE1 was associated 
with FACT complex in both cell lines. Three biological replicates were performed and 





Figure 61. Confocal microscopy demonstrates the colocalization of AcAPE1 and 
FACT complex.  
To provide further evidence of the interaction of AcAPE1 and FACT complex, HD-MB03 
and ONS-76 cells were stained with AcAPE1, SSRP1 and SPT16 antibodies. The 
expression and co-localization of SSRP1, SPT and AcAPE1 was examined using confocal 
microscopy. The colocalization was visualized on merged images. Multiple cells from three 





Figure 62. Increased association of AcAPE1 and FACT complex upon irradiation is 
observed.  
To examine if radiation affects the interaction of AcAPE1 and FACT complex, we irradiated 
(5 Gy) HD-MB03 cells and performed immunoprecipitation using AcAPE1 antibody. IgG 
was used as negative control. We found that irradiation significantly increased the 
association of AcAPE1 and FACT complex. Three biological replicates were analyzed. 





Figure 63. Confocal microscopy demonstrates increased colocalization of AcAPE1 
and FACT complex upon irradiation treatment.  
To provide further evidence that irradiation increases the interaction of AcAPE1 and FACT 
complex, cells were irradiated with 2 Gy and submitted for immunofluorescence staining 
with corresponding antibodies. We found that irradiation enhanced the colocalization of 
AcAPE1 and both subunits of FACT complex. Multiple cells in three biological replicates 
were analyzed. Representative images were shown. Bar = 25 μM. 
 




To examine whether FACT facilitates the binding and acetylation of APE1 at 
damage sites in chromatin, we used siRNA to downregulate SPT16 and SSRP1 together 
(FACT siRNA) (Fig. 64). FACT siRNA successfully decreased the expression of SPT16 
and SSRP1 which resulted in reduction of AcAPE1 level. The total APE1 expression 
remained unchanged. As acetylation of APE1 occurs after binding to AP site in chromatin, 
these data indicate that the absence of FACT complex significantly reduced the access or 
binding of APE1 to damage sites and its subsequent acetylation in chromatin. Previously, 
we showed that APE1 regulates p21 expression via binding to the p21 and DTL proximal 
promoter regions and functions as a coactivator or corepressor depending on the p53 
status of the cells (95). To understand if FACT facilitates the recruitment and/or binding of 
APE1 to damage sites in p21 and DTL promoters, we treated the cells with 5 Gy radiation 
with control and FACT siRNA, respectively. We performed ChIP assays with APE1 
antibody. Consistently, ChIP assay revealed that FACT downregulation significantly 
abrogated the occupancy of APE1 to p21 and DTL promoters upon radiation damages 
(Fig. 65). Together, these data provide evidence that the FACT complex promotes the 
binding and subsequent acetylation of APE1 to damage sites in chromatin. Next, we 
tested if FACT knockdown impacted the DNA repair function of APE1. FACT knockdown 
cells demonstrated undetectable level of AcAPE1 as compared to normal cells (Fig. 66). 
While cisplatin increased the colocalization of SSRP1 and AcAPE1 in nucleus, FACT 
knockdown abrogated the effect of cisplatin on inducing AcAPE1. The interference of 
FACT knockdown on BER function was further examined using neutral comet assay which 
measures DNA double-strand breaks. Cells treated control siRNA showed DNA damage 
after 5 Gy radiation, and the damages were repaired at 24-hour release (Fig. 67). On the 
other hand, FACT siRNA treated cells failed to repair the DNA damage despite 24-hour 
release. These data indicate that the interaction of FACT complex and AcAPE1 can be 




Figure 64. FACT KD decreases the expression of AcAPE1 but not total APE1.  
To examine if FACT knockdown affects the level of AcAPE1, we used siRNAs of SPT16 
and SSRP1 to deplete FACT complex. The expression levels of SPT16, SSRP1, AcAPE1 
and APE1 were examined by Western blot analysis. We found that the level of AcAPE1 
decreased upon FACT knockdown while total APE1 level stayed stable. Two biological 





Figure 65. FACT KD abrogates the enhanced occupancy of AcAPE1 to p21 and DTL 
promoter regions upon irradiation.  
To investigate whether FACT complex affects the binding of AcAPE1 to p21 and DTL 
promoter regions, the cells were transfected with siRNAs of FACT complex and 48 hours 
after transfection cells were then exposed to 5 Gy irradiation. The binding/occupancy of 
AcAPE1 to p21 (Top) and DTL (Bottom) promoter regions were examined using promoter-
directed real-time PCR assay. Note that FACT siRNA means siRNAs of SPT16 plus 
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SSRP1. Green asterisks mark the comparisons between ctrl siRNA and FACT siRNA 
without irradiation treatment. This indicates that FACT depletion under physiological 
condition leads to decreased AcAPE1 occupancy to both promoter regions. Red asterisks 
mark the comparisons between ctrl siRNA and FACT siRNA at the presence of irradiation. 
While in control cells AcAPE1 occupancy increased upon irradiation, such effect was 
abrogated by FACT depletion. Three biological replicates were performed. Results are 
shown as the mean ± SEM. One-way ANOVA with Tukey's HSD test, ** p<0.01, *** 





Figure 66. SIM demonstrates that the enhanced colocalization of SSRP1 and 
AcAPE1 upon cisplatin treatment is abrogated by FACT KD.  
Beside irradiation, cisplatin-based chemotherapy is another mainstay of treatment for MB. 
We sought to test if cisplatin increased the colocalization of AcAPE1 and FACT complex, 
and if such effect would be affected by FACT knockdown. The expression of SSRP1 and 
AcAPE1 were examined after treatment with cisplatin or FACT knockdown, and 
combination (FACT knockdown plus cisplatin). As demonstrated by SIM, while cisplatin 
increased the colocalization of AcAPE1 and SSRP1, the enhancement was prevented by 
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FACT depletion. Three biological replicates were performed. Representative images were 




Figure 67. FACT KD significantly impairs BER repair on irradiation induced damage.   
(Top) Neutral comet assay was performed to detect the DNA damage induced by 
irradiation. Note that we used neutral comet assay which allows the detection of double-
strand breaks by subjecting lysed cell nuclei to an electrophoretic field at a neutral pH (7). 
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This is different from alkaline comet assay which was used in Chapter 1, in the way that it 
uses alkaline pH (13) to allow for single strand break detection. Cells were transfected 
with control or FACT siRNA and submitted to irradiation at indicated dose. 24-hour release 
was given to allow DNA repair. (Bottom) Tail moment of 50 cells was examined in each 
treatment group and the bar graph was shown. In control and FACT KD groups, 5 Gy 
irradiation induced a significant amount of DNA damage as evident by the rise of tail 
moment. The difference, however, was at 24-hour release. The FACT siRNA treatment 
resulted in failure to repair DNA damage, while control cells had recovered with baseline 
tail moment. Three biological replicates were analyzed. Results are shown as the mean ± 
SEM. One-way ANOVA with Tukey's HSD test, *** p<0.001, **** p<0.0001. 
 
Inhibition of FACT complex with Curaxin/CBL0137 abrogates the binding and 
acetylation of APE1 to damage site in chromatin. 
We further examine if FACT complex can be targeted using a readily available 
agent, curaxins.  Curaxins is a class of small molecule drugs with broad anticancer activity. 
It unfolds nucleosomes and traps FACT in unfolded nucleosomes chromatin. CBL0137 is 
the second generation curaxins that modulates several important signaling pathways 
through inhibition of FACT function. Consistent with prior reports, CBL0137 decreased the 
protein levels of SSRP1 and SPT16 in soluble whole cell lysates in a dose-dependent 
manner (Fig. 68). In contrast, SSRP1 and SPT16 levels increased in chromatin extracts 
with a concurrent reduction in nuclear extracts (Fig. 69 & 70). This is the chromatin 
trapping effect induced by CBL0137. We found inhibition of FACT with CBL0137 
decreased AcAPE1 and FACT colocalization (Fig. 71). These data indicate that inhibition 
of FACT with curaxins reduced APE1-binding to the damage sites and its subsequent 





Figure 68. CBL0137 decreases the expression of AcAPE1 and FACT complex in 
whole cell extracts of MB cells.  
To investigate the effect of CBL0137 on the expression of interested proteins, cells were 
treated with indicated doses of curaxins/CBL0137 (CX). Whole cell extract was used for 
Western blotting to examine the expression levels of SPT16, SSRP1 and AcAPE1. We 
found that CBL0137 decreased the level of AcAPE1 in a dose-dependent manner in HD-
MB03 and ONS-76 cells. Such effect could also be observed on SSRP1 and SPT16 levels. 





Figure 69. CBL0137 causes chromatin trapping effect on FACT complex and 
decreases the expression of AcAPE1 in HD-MD03 cells.  
Here, we performed Western blot analysis of SPT16, SSRP1 and AcAPE1 in soluble 
nuclear fraction and chromatin extracts in HD-MB03 cells after treatment with CBL0137. 
H2A was used as internal control. We found that similar to our previous finding, chromatin 
trapping effect was present in HD-MB03 cells, as demonstrated by decreasing level of 
FACT complex in nuclear extract but increasing level in chromatin extract. Three biological 





Figure 70. CBL0137 causes chromatin trapping effect on FACT complex and 
decreases the expression of AcAPE1 in ONS-76 cells.  
Following the prior experiment, we sought to confirm the chromatin trapping effect of 
CBL0137 in ONS-76 cells. ONS-76 cells were treated with CX. Nuclear and chromatin 
extracts were used to examine the expression levels of SPT16, SSRP1 and AcAPE1. H2A 
was used as internal control. We found that CBL0137 treated cells had dose-dependent 
decrease of FACT complex in nuclear extract and dose-dependent increase in chromatin 
extract, consistent with chromatin trapping effect. Three biological replicates were 





Figure 71. CX decreases the expression of AcAPE1 and its colocalization with FACT 
complex.  
To visualize the effect of CX on the expression and its interaction with FACT complex, 
cells were treated with CX and submitted for immunofluorescence staining. As 
demonstrated by confocal microscopy, CX treatment decreased the expression of 
AcAPE1 and the colocalization with FACT complex in HD-MB03 cells. Multiple cells in 





Inhibition of FACT function with Curaxin/CBL0137 delayed radiation and cisplatin-
induced DNA damage repair. 
As FACT promotes binding and subsequent acetylation of APE1, we deduced that 
cells would accumulate SSBs or DSBs in the genome in the presence of FACT inhibitor. 
To provide evidence for the role of FACT in facilitating the radiation induced DNA damage 
repair in cells, we used single cell alkaline comet assay which detects both SSBs and 
DSBs damages in the genome in cells after curaxin treatment (Fig. 72 & 73). Cells 
exhibited tails indicative of DNA damages after radiation exposure or cisplatin treatment 
and started to recover in 24-36 hours. However, curaxin-treated cells retained significantly 
more tails in 24 hours. These suggest that in the presence of curaxin cells fail to efficiently 
repair radiation and cisplatin-induced DNA damages.  
 
 
Figure 72. CX impaired DNA damage repair after irradiation.  
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To examine the effect of CX on the DNA repair activity, cells were irradiated with and 
without CX pretreatment. Neutral comet assay was used to detect DNA damage. 36-hour 
release was given to allow for DNA repair. We quantified the result with tail moment and 
presented in next figure. 
 
 
Figure 73. CX-treated cells fail to repair irradiation induced damages after 36-hour 
release.  
Average Tail moment of 50 cells was examined in each treatment group and mean ± SEM 
was shown in the bar graph. We found that 5 Gy induced DNA damages as evident by 
significant rise of tail moment in both groups. However, CX-treated cells were unable to 
repair the damages after 36-hour release, indicating the inhibitory effect of CX on DNA 
repair activity. Three biological replicates were analyzed. One-way ANOVA with Tukey's 




Curaxin/CBL0137 treatment sensitizes MB cell lines to cisplatin and irradiation in 
vitro 
Since our studies and others show that FACT is involved in SSBs or crosslinks 
damages repair in cells, we examined whether targeting FACT with CBL0137 enhanced 
the efficacy of radiation and cispaltin in MB cells in vitro. To eliminate the possibility that 
CBL0137 show cytotoxic effect per se by inducing DNA damages, cells were treated with 
different doses of CBL0137 alone. We found 4 μM CBL0137 alone had a minimal effect 
(20% cell death) on cell viability and colony formation (Fig. 74 & 75). However, 
combination of 4 μM CBL0137 with 5 Gy radiation significantly enhanced the sensitivity of 
HD-MB03 and ONS-76 cells to radiation and cisplatin (Fig. 76 & 77), suggesting that 
targeting FACT complex with curaxins could be a promising strategy to sensitizes these 
MB cells in vivo.  The IC50 of cisplatin on HD-MB03 cells dropped from 3.8 μM to 0.47 
μM, and the IC50 of cisplatin on ONS76 cells dropped from 1.2 μM to 0.67 μM, 
demonstrating a synergistic effect. In addition, we performed colony formation to examine 
the effect of CBL0137 (Figure 78 & 79). CBL0137 increased the sensitivity of cisplatin 
(noticeable at lowest dose of 0.5 μM) and irradiation (noticeable at lowest dose of 2 Gy). 
Together these data suggest that CX causes impaired DNA repair, exhibiting synergistic 





Figure 74. CX alone has minimal effect on cell viability.  
To eliminate the possibility that CX affects cell viability per se, HD-MB03 and ONS-76 cells 
were treated with CX alone at indicated doses and MTT assay was performed to 
investigate the cytotoxicity of CX. We found that CX treatment had minimal effect on cell 
viability, suggesting its minimal toxicity when administered alone to cells. Three biological 





Figure 75. CX alone has minimal inhibitory effect on colony formation assay.  
To provide further evidence of the minimal anti-proliferative effect of CX, HD-MB03 and 
ONS-76 cells were treated with CX alone and colony formation assay was performed. As 
demonstrated by the bar graph, we did not find significant effect of CX on colony formation 





Figure 76. CX sensitizes HD-MB03 and ONS-76 cells to cisplatin.  
To investigate whether CX could be used as a chemosensitizing agent for MB therapy, we 
pretreat cells with CX and then exposed cells to indicated doses of cisplatin. MTT assay 
was used to examine the cell viability. Two cell lines including HD-MB03 and ONS-76 
were used. We found that CX improved the treatment efficacy of cisplatin at a dose as low 
as 0.1 μM for HD-MB03 cells, and 1 μM for ONS-76 cells. We also found synergistic effect 
when combining cisplatin and CX, suggesting that the combination treatment may be a 
promising strategy to achieve similar treatment outcome with lower drug dose. Green 
asterisks mark the comparison between HD-MB03 control and CX-treated cells, and 
orange asterisks mark the comparison between ONS-76 control and CX treated cells. Six 
technical repeats were performed per sample and three biological replicates were 
analyzed. Results are shown as the mean ± SEM. One-way ANOVA with Dunnett's post-





Figure 77. CX significantly decreases cell viability in radiation treatment.  
To test if CX could be used to sensitize MB cells to radiation, MTT assay was used to 
examine the effect of CX combined with various doses of irradiation. Two cell lines 
including HD-MB03 and ONS-76 were used. We found that combination of CX with 
radiation demonstrated improved inhibitory effect on cell viability in both cell lines at dose 
as low as 1 Gy. Green asterisks mark the comparison between HD-MB03 control and CX-
treated cells, and orange asterisks mark the comparison between ONS-76 control and CX 
treated cells. Six technical repeats were performed per sample and three biological 
replicates were analyzed. Results are shown as the mean ± SEM. One-way ANOVA with 






Figure 78. Combination therapy with cisplatin plus CX results in significant 
inhibition on colony formation in MB cells.  
To examine whether addition of CX provides anti-proliferation effect of MB cells, cells were 
treated with CX and various doses of cisplatin. The effect of treatment was examined using 
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colony formation. Representative images of colonies were shown. Quantification of colony 
numbers in each group were plotted. Three technical repeats were performed per sample 
and three biological replicates were analyzed. Results are shown as the mean ± SEM. We 
found that the CX sensitized HD-MB03 cells to cisplatin as evident by significantly less 
colony number at a dose as low as 0.1 μM. The effect could also be observed in ONS-76 
cells, however, only evident in doses of 0.5 and 1 μM cisplatin, indicating a relatively 
narrow therapeutic window to gain benefit by adding CX. An alternative interpretation of 
this result is that similar inhibitory effect could be achieved by combining CX and 5-FU at 
a lower dose. This is of importance in order to lower the toxicity of cisplatin. Green 
asterisks mark the comparison between HD-MB03 control and CX-treated cells, and 
orange asterisks mark the comparison between ONS-76 control and CX treated cells. 






Figure 79. Combination therapy with radiation plus CX results in significant 
inhibition on colony formation in MB cells.  
To examine whether addition of CX provides superior effect on anti-proliferation of MB 
cells upon irradiation, cells were treated with CX and various doses of irradiation. The 
effect of treatment was examined using colony formation. Representative images of 
colonies were shown. Quantification of colony numbers in each group were plotted. Six 
technical repeats were performed per sample and three biological replicates were 
analyzed. Results are shown as the mean ± SEM. We found that CX sensitized MB cells 
to radiation treatment, as demonstrated by significant inhibition of colony formation at a 
dose as low as 1 Gy and 2 Gy in HD-MB03 and ONS-76 cells, respectively. Green 
asterisks mark the comparison between HD-MB03 control and CX-treated cells, and 
orange asterisks mark the comparison between ONS-76 control and CX treated cells. 
One-way ANOVA with Dunnett's post-hoc test, * p<0.05, ** p<0.01. 
 
Combination of CX and cisplatin inhibits xenograft MB tumor growth in vivo 
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To examine whether inhibition of FACT with curaxins sensitizes MB cells to 
cisplatin and inhibits tumor growth in vivo, we utilized tumor xenograft models. We 
established xenograft models by subcutaneous inoculation of HD-MB03 cells with Matrigel. 
At two weeks after inoculation, tumors became visible and palpable. Mice were then 
randomly divided into 4 groups. The effects of CBL0137 and cisplatin were tested alone 
and in combination. Tumor growth curve showed that single agent treatment with 
CBL0137 alone had very little or moderate effect on tumor growth compared to vehicle 
group (Fig. 80), while combination of cisplatin and CBL0137 significantly inhibited tumor 
growth, demonstrating a synergistic effect. The combination of cisplatin with CBL0137 was 
well tolerated at the scheduled doses and there was no significant weight loss observed 
(Fig. 81). There was no major histological abnormality identified in vital organs including 
lung, liver and kidney (Fig. 82). Further analysis showed that combination group 
suppressed the proliferation and increased apoptosis, evident by decreased Ki-67 staining 
and increased TUNEL staining significantly in combination group (Fig. 83 & 84). This was 
further confirmed by IHC staining of caspase-3 and its cleavage target, PARP-1 (Fig. 85). 
In consistent with in vitro result, CX treatment decreased the staining intensity of SSRP1 
and AcAPE1 in these tumor sections (Fig. 86). Together these data suggest that CX 
augments cisplatin treatment in vivo, and the combination decreases cellular proliferation 






Figure 80. Combination of cisplatin plus CX inhibits HD-MB03 xenograft growth with 
synergistic effect.  
To test whether combination therapy affect MB growth in vivo, we used xenograft model 
by implanting HD-MB03 cells (1×106 in 100 μl medium) subcutaneously over the left and 
right flanks in athymic nude mice (n=5). When tumor volume reached 100 mm3, mice were 
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randomly divided into four groups. Vehicle (100 μL PBS), cisplatin, CBL0137 and 
combination of cisplatin and CBL0137 were administered to mice intraperitoneally every 
other day for 3 weeks. (Top) Resected xenograft tumor after completion of treatment were 
shown. (Bottom) Tumor volume was measured at indicated days and tumor growth curve 
was plotted. We calculated the average of two xenograft tumors in each mouse, and then 
calculated the SEM of each treatment group. Caution should be taken as n=5 which would 
make it difficult to detect difference among groups and may lead to statistical error. Future 
studies should use larger number of mice in each group to verify the findings we reported 
here. We found that monotherapy with cisplatin or CX caused mild inhibitory effect on 
tumor growth, while combination therapy demonstrated markedly inhibition on xenograft 
volume with synergistic effect. This indicates that the combination treatment may serve as 
a new treatment strategy to sensitize MB to cisplatin. Kruskal-Wallis test with Games-





Figure 81. No significant weight change of mice was observed throughout treatment 
period.  
Weight loss or cachectic appearance is an indicator of treatment toxicity. We measured 
the weight of each mouse each time before the treatment and until the completion of the 
treatment. There was no significant change in weight in each group (n=5), suggesting well 





Figure 82. H & E staining demonstrates no major toxicity in major organs after 
treatment.  
To provide further evidence that the treatment is well tolerated, we performed histology 
examination of major organs including heart, liver, spleen, lung and kidney in mice of all 
treatment group. There is no histological change among treatment groups in major organs. 
Organs from three independent mice from each group were analyzed. Representative 





Figure 83. IHC staining of xenograft tumor demonstrates anti-proliferative and pro-
apoptotic effect of combination therapy.  
To understand the underlying mechanism of the inhibitory effect on tumor growth from 
combination therapy, we used various markers and performed IHC on xenograft tumor 
sections. Representative images in each group were shown. Quantification of each 





Figure 84. Combination therapy exhibits anti-proliferative and pro-apoptotic effects 
on MB xenograft tumors.  
Bar graph depicting the percentage of positive staining cells for TUNEL (Top) and Ki-67 
(Bottom). In each group, xenograft section form three independent mice were chosen and 
images from 10 random high power fields in were used for quantification. We found that 
combination therapy exhibits anti-proliferative and pro-apoptotic effects on MB xenograft 
tumors. The effects were significant when compared with monotherapy either by cisplatin 






Figure 85. Combination therapy decreases the expression of AcAPE1 and SSRP1 in 
MB xenograft tumors.  
We have shown that levels of AcAPE1 and SSRP1 were elevated in MB cell line. Here, 
we sought to determine the effect of combination therapy on the expression of both 
proteins. In each group, xenograft section form three independent mice were chosen and 
images from 10 random high power fields in were used for quantification. Bar graph 
depicting the mean ± SEM of positive staining cells for SSRP1 (Top) and AcAPE1 (Bottom). 
We found that CBL0137 alone resulted in decreased level of SSRP1. Combining cisplatin 
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and CBL0137 lead to significantly reduction of SSRP1 when compared to CBL0137 or 
control group. In regard to AcAPE1, cisplatin treatment decreased the expression of 
AcAPE1, and combination treatment further caused suppression of AcAPE1 level. 
Together these data suggest that combination therapy results in significant reduction of 
AcAPE1 and SSRP1 level, which is superior to monotherapy. One-way ANOVA with 






Radiation and platinum–based chemotherapy is effective against a variety of 
pediatric cancer including MB. Unfortunately, the use of high dose cisplatin and radiation 
leads to neurotoxicity and progressive or permanent hearing loss which can affect the 
quality of life of childhood cancer survivor, highlighting the need for novel therapeutic 
targets to increase efficacy of chemoradiation therapy. In this study, we have identified 
FACT complex as a novel target to sensitize MB cells to cisplatin and radiation both in 
vitro and in vivo. Furthermore, we show that FACT complex functionally interacts with 
APE1 and promotes radiation and cisplatin resistance. FACT facilitates the recruitment 
and acetylation of APE1 at damage sites and promoting radiation and chemo-induced 
DNA damages repair. FACT inhibitor CBL0137/curaxin effectively inhibits DNA damage 
repair. We have provided multiple lines of evidence to demonstrate that targeting FACT 
complex with curaxins significantly improves the efficacy of chemotherapy and radiation 
in vitro and in vivo preclinical mouse model. Our study demonstrates that targeting FACT 
with curaxins is a promising strategy to sensitize MB cells to radiation and cisplatin and 
could be used as an adjuvant therapy to lower the side effects in MB patients.  
Our data show that MB patients’ tissues have elevated levels of both FACT and 
APE1 levels and FACT physically and functionally interact with APE1 in MB cells. 
Overexpression of APE1 in MB and its association with radiation and chemotherapy 
resistance as well as poor prognosis are well documented. APE1 primarily repairs AP sites 
or SSB, common intermediates in the BER pathway that are generated after radiation and 
many chemotherapeutic drugs, including cisplatin (2). The repair of AP sites or SSBs by 
APE1 on naked DNA or nucleosomal DNA substrate has been extensively investigated in 
vitro (115). However, DNA in the eukaryotic cell is packaged into nucleosome in chromatin. 
Thus, cells must repair DNA lesions including AP sites within the context of nucleosome 
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chromatin. Nucleosome, composed of a 147-bp segment of DNA helix wrapped around a 
histone protein octamer, serves as the basic unit of chromatin. However, to date, how 
APE1 repairs AP sites in the context of the nucleosome in chromatin remains largely 
unknown. Here, we show that APE1 interacts with nucleosome remodeling histone 
chaperone FACT complex. We found that FACT is required for recruitment and binding of 
APE1 to damage sites in chromatin. Histone chaperone is a group of proteins that bind 
histones and regulate nucleosome assembly and disruption. FACT complex as a histone 
chaperone possess versatile functions in vivo (154). FACT complex interacts with RNA 
polymerases (155,156) and facilitates transcription by disrupting nucleosomes in their path 
and by aiding in the redeposition of histones post-transcription (60,157). Moreover, 
increasing evidence suggests that FACT is involved in multiple DNA damage repair 
pathways. It has been shown that H2A and H2B are evicted and replaced at an 
accelerated pace at sites of UV-induced DNA damage by SPT16 subunit, and FACT is 
present in active transcription-coupled NER (TC-NER) repair complexes (64). SPT16 
interacts with UV-Stimulated Scaffold Protein A (UVSSA) which is mediated by the 
DUF2043 domain and stimulates TC-NER-mediated repair (158). Additionally, FACT has 
been shown to act in concert with RSC to facilitate excision of DNA lesions during the 
initial step of BER (159). This is consistent with the various function of FACT complex, 
given its ability to modulate nucleosome. Notably, we show that downregulation of FACT 
complex inhibits DNA damage repair and sensitizes tumor cells to many chemotherapeutic 
agents. Thus our study provides the first evidence of involvement of histone chaperone 
complex in regulating damage repair in chromatin in cells and identifies FACT complex as 
a novel target for sensitization of tumor cells to chemotherapeutic drugs. As APE1 and 
FACT complex are both upregulated in MB, it is possible that both proteins are implicated 
in the treatment response and prognosis. Indeed, as shown in our results, APE1 and FACT 
overexpression is associated with poor survival. While APE1 can be targeted, FACT 
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complex is a more appealing target for the following reasons. First, FACT complex is 
involved in multiple DNA repair pathways, and share a common role in nucleosome 
modulation. Second, reports have shown that FACT complex is undetectable in normal 
cells of adult mammalian tissues, except for undifferentiated and stem-like cells. It is 
upregulated during in vitro transformation and promotes survival and growth of established 
tumor cells (97). Such differential expression among normal and tumor tissues is 
advantageous in lowering side effects when it comes to treatment. Third, there is no 
available molecule that target APE1 DNA repair function with high efficacy in vivo (160), 
but there is readily available anticancer small molecule curaxin which effectively inhibits 
FACT functions in cells and s under clinical trial for other solid tumors. 
Curaxins is a group of small molecules that were identified in a phenotype-based 
screening for the ability to simultaneously activate p53 and inhibit NF-κB without causing 
detectable genotoxicity (66). Curaxins have caught increasing attentions since the 
initiation of clinical trial. The first clinical phase I trial was launched in July 2013 to 
determine the maximally tolerated dose and recommended phase II dose of CBL0137 
when administered intravenously (IV) to patients with metastatic or unresectable 
advanced solid malignancies (NCT01905228). Since then, two clinical trials with broader 
application were started for those with hematological malignancies, metastatic extremity 
melanoma or sarcoma (NCT02931110 and NCT03727789). In search for its mechanism 
of action, it was discovered that curaxins bind DNA without causing detectable DNA 
damages (67) and binding of curaxins leads to uncoiling or unfolding of nucleosome. 
Nucleosome disassembly caused by curaxins opens multiple FACT-binding sites, which 
are normally hidden inside the nucleosome and trap FACT in chromatin. Our data show 
CX inhibits FACT complex and causes impaired DNA repair, exhibiting synergistic effect 
with cisplatin and sensitizes irradiation. Importantly CX augments cisplatin treatment in 
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vivo, and the combination decreases cellular proliferation and causes apoptosis. FACT 
inhibitor CBL0137 has been shown to synergize with cisplatin in small cell lung cancer by 
increasing Notch signaling and targeting tumor initiating cells (126). Dermawan et al. 
reports that FACT expression was elevated in glioblastoma multiforme (GBM) tumors 
compared with non-neoplastic brain tissues, portended a worse prognosis, and positively 
correlated with glioblastoma stem cells markers and stem cell gene expression signatures. 
Lapatinib and CBL0137 synergistically inhibited the proliferation of patient-derived GBM 
cells and prolongs the survival of mice bearing orthotopic GBM (103). In addition, 
CBL0137 monotherapy was tested against the Pediatric Preclinical Testing Program 
(PPTP) in vitro cell line panel and against the PPTP in vivo solid tumor xenograft and 
acute lymphocytic leukemia (ALL) panels (161). Nonetheless, here we add to the current 
knowledge by providing compelling evidence that curaxins exhibit strong synergy with 
cisplatin and radiation in killing MB cells by inhibiting DNA damage repair.  
In conclusion, here we report for the first time that APE1 and FACT complex 
overexpression in MB is associated with poor prognosis. FACT complex interacts with 
APE1 and facilitates the access of APE1 to damage sites which in turn promotes DNA 
damage repair. Targeting FACT complex with small molecules CBL0137/curaxin 
significantly improves the efficacy of cisplatin and radiation in vitro and in vivo in a 
preclinical model. The readily available FACT inhibitor, CBL0137, represents a highly 
translatable and targeted therapeutic approach that can be used clinically as an adjuvant 
therapy to sensitize MB patients to lower the side effects of current standard therapy in 





           In the current study we provided biochemical evidence that FACT complex plays 
an important role in BER pathway. FACT complex interacts with APE1 and facilitates its 
access to chromatin and subsequent acetylation. Enhancement of their physical 
interactions upon DNA damage highlights the requirement of their physical interaction in 
response to DNA damages. Furthermore, the significance of their functional interaction is 
evident from the facts that FACT knockdown by siRNA complex or blocking FACT function 
with Curaxins significantly impairs APE1 functionality in BER pathway and leads to 
delayed repair of DNA damages and sensitizes cells to DNA insulting agents or radiation. 
          While this is a comprehensive study that provides multiple lines of evidence to 
understand the functional interaction of FACT complex and APE1 and the efficacy of 
combination therapy in cancer treatment, there are several unanswered questions remain 
to be addressed. 
          As shown in Chapter 1, both subunits of FACT complex including SPT16 and 
SSRP1 are identified in the immunoprecipitation using antibody directing at AcAPE1. It is 
unknown where the interaction occurs. We immunoprecipitated FLAG-tagged WT-APE1 
and nonacetylable K5R mutant from nuclear fractions. No significant differences were 
observed in the amount of SPT16 bound with WT and non-acetylable K5R APE1 IPs, 
indicating that acetylation of APE1 is not essential for its interaction with FACT complex 
Therefore we propose that FACT complex interacts with APE1 before acetylation. Our 
experiments also demonstrate that knockdown of FACT complex will not affect the 
expression of APE1 but instead cause decrease in AcAPE1 level. It is possible that FACT 
complex interacts with APE1 and brings it to the chromatin. Alternatively, FACT complex 
creates transiently accessible nucleosome structure to allow APE1 access to damage 
sites. Additionally, while SPT16 and SSRP1 both interact with APE1, it remains unclear 
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what domain is responsible for such interaction. All eukaryotic forms of the SPT16 protein 
are composed of three distinct structurally defined domains in combination with a 
negatively charged intrinsically disordered C-terminal domain termed here as the N-
terminal domain (NTD), the dimerization domain (DD), the middle domain (MD), and C-
terminal domain (CTD). Previously, genetic analysis has provided evidence for a 
functional relationship between the yeast Spt16 NTD and the C-terminal “docking domain” 
extension of H2A, whereas concurrent mutations within both domains cause lethality in 
yeast. On the other hand, the human SSRP1 protein contains three well defined domains 
designated the NTD/DD, the MD, and the HMG-1 domain. HMG domains can readily bind 
to nucleosomal DNA and may help FACT recognize, bind, and effectively reorganize 
chromatin. The question of what domain in each subunit of FACT complex interacts with 
APE1 remains to be investigated. To determine which domain of FACT is involved in the 
interaction with APE1, we will design several Flag-tagged both N- and C-terminal deletion 
mutants of SPT16 and SSRP1. We will overexpress these mutants one at a time in cells 
and isolate the chromatin extract by cell fractionation. Afterwards, we will check the 
interaction of these FLAG mutants with APE1 and/or AcAPE1. 
         While we provide evidence that targeting FACT complex can significantly impair the 
BER function, it is possible that FACT knockdown has effects on other DNA repair 
pathways and on gene expressions. FACT complex belongs to histone chaperones which 
is a diverse family of histone-binding proteins that shield non-nucleosomal histone-DNA 
interactions. Histone chaperones are involved in multiple cellular processes, including 
gene transcription, DNA replication, and DNA repair. Therefore knockdown of FACT 
complex will affect all these processes that can have different effect on cellular 
proliferation and growth. As we mentioned earlier, FACT complex is also involved in NER. 
Study has showed that the SPT16 subunit of the histone chaperone FACT interacts with 
144 
 
UVSSA, which is mediated by the DUF2043 domain. SPT16 is recruited to transcription-
blocking DNA lesions, independently of UVSSA, to stimulate UVSSA recruitment and TC-
NER-mediated repair. It is also involved in homologous recombination repair. More 
recently, SSRP1 has been shown to be recruited to SSB in PARP-dependent manner and 
retained at DNA damage sites by N-terminal interactions with the DNA repair protein 
XRCC1. These reports along with our data have suggested that FACT complex is involved 
in more than one pathway, and it has multiple effects that are not clearly delineated.  
            We have shown that curaxins demonstrates minimal toxicity at the doses we 
administered while exhibiting synergistic effects with chemotherapeutic agents and 
radiation. Future study should be directed at systematic pharmacologic study to 
understand its pharmacokinetics and toxicity. Curaxins is first identified in a phenotype-
based screening for the ability to simultaneously activate p53 and inhibit NF-κB without 
causing detectable genotoxicity (66). In search for its mechanism of action, it was 
discovered that curaxins bind DNA via intercalation of the carbazole body accompanied 
by the protrusion of two side chains into the major groove and a third side chain into the 
minor groove of DNA, inducing tight binding of FACT to chromatin that results in functional 
inhibition (67). Later, Safina et al reports that binding of curaxins leads to uncoiling of 
nucleosomal DNA, accumulation of negative supercoiling and conversion of multiple 
regions of genomic DNA into left-handed Z-form. Nucleosome disassembly caused by 
curaxins opens multiple FACT-binding sites, which are normally hidden inside the 
nucleosome. The isolated C-terminal intrinsically disordered domain (CID) of SSRP1, but 
not HMG domain, binds these alternative DNA structures and triggers p53 response (68). 
While it is claimed to be FACT inhibitor, curaxins causes chromatin trapping effects 
instead of binding directly to either subunits. The effects of curaxins on multiple gene 
expression can be explained by its mechanism of action as it affects FACT complex which 
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is essentially involved in DNA transcription and repair process. We can obtain RNA-seq 
of curaxins-treated cells to understand the global aspect of the effects on gene expression. 
 In our in vivo study to test the efficacy of combination therapy, subcutaneous 
xenograft models were used. Tumor xenografts are easy to use and reproducible, but they 
carry potential limitations that genetics and histology of the tumors are frequently not 
representative of the respective human tumor. Therefore, these models have not been as 
predictive of therapeutic success as one would like. By contrast, genetically engineered 
mouse model (GEMs) are histologically and genetically accurate models of human cancer 
as these mice develop de novo tumors in a natural immune-proficient microenvironment 
(162,163). GEMs are superior in mimicking the histopathological and molecular features 
of their human counterparts, displaying genetic heterogeneity, and are able to 
spontaneously progress toward metastatic disease. These have been used to validate 
candidate cancer genes and drug targets, assess therapy efficacy, and evaluate 
mechanisms of drug resistance at pre-clinical studies (163).  
Msh2 gene was found to be one of the most commonly mutated MMR in CRC 
patients. Mutations in Msh2 cause Lynch syndromes I and II and sporadic colorectal 
cancers, which constitute about 15% of colon cancer. Previously three Msh2null knockout 
mouse lines have been generated in the hope of developing mouse model for Lynch 
Syndrome. Homozygous mutant mice of all three Msh2null knockouts, though MMR-
deficient, develop lymphoma predominantly (164-166). Recently a novel conditional 
knockout mouse model for the tissue-specific inactivation of Msh2 (Msh2LoxP) has been 
reported (167). In this model, MMR can be inactivated by Cre-LoxP-mediated inactivation 
of Msh2 in different tissues by the expression of various Cre-recombinase transgenes. 
The Msh2LoxP allele can be combined with the Villin-Cre transgene (VCMsh2LoxP) to 
specifically inactivate MMR in the intestinal mucosa. These mice develop exclusively 
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intestinal neoplasms. In future study, we can obtain conditional Msh2 knockout (Msh2loxp) 
and Villin-Cre transgenic mice from Jackson lab (Stock No. # 016231 and # 021504). 
Msh2loxp/+ will be crossed with Villin-Cre transgenic mice to generate VCMsh2loxp/+. 
Heterozygotes will be intercrossed to generate VCMsh2loxp/loxp. Msh2 inactivation from 
intestine will be confirmed by RT-qPCR analysis. VCMsh2loxp/loxp mice generally form 
intestine tumor after 7 months (167). Colonic tumor growth in these mice will be monitored 
on a longitudinal basis using Carl Stroz small animal endoscope in collaboration with Dr. 
Amar Singh. Once we have ascertained tumor growth in these mice, mice will be divided 
into three groups, each with 8 mice (4 male, 4 female). The first groups will receive 
vehicles, the second will receive IP injection with 20 mg/kg 5-FU, and the third will receive 
a combination of CBL0137 30 mg/kg and 20 mg/kg 5-FU every other day for three 
weeks.  Tumor growth will be monitored using the colonoscope, which will also help 
determine the appropriate timing for sacrificing these mice. Post-sacrifice, mice will be 
examined for the tumor multiplicity and tumor volume. We will quantitate colonic apoptosis 
using TUNEL assay and proliferating cells with Ki67 staining in these tissue sections.  
Similarly, we can obtain GEMs or orthotopic tumor model of medulloblastoma and 
tested the efficacy of CBL0137. Another problem we may encounter is the ability to cross 
blood brain barrier (BBB). This is a practical question as any medication that targets 
medulloblastoma needs to cross BBB in order to reach target. This also reflects the 
importance of using GEMs instead of subcutaneous xenograft model in future study to 
validate the efficacy of curaxins. Barone et al. implanted the glioblastoma cells 
orthotopically in nude mice and administered CBL0137 in various dosing regimens to 
assess brain and tumor accumulation of CBL0137 (168). Interestingly, CBL0137 
penetrated the blood-brain barrier and accumulated in orthotopic tumors significantly more 
than normal brain tissue. It increased apoptosis and suppressed proliferation in both 
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U87MG and A1207 tumors. This may be explained by another study, where FACT 
complex was reported to be not expressed in normal cells of adult mammalian tissues, 
except for undifferentiated and stem-like cells (97). In addition, FACT was found to be 
upregulated during in vitro transformation and to be necessary, but not sufficient, for 
driving transformation. FACT also promoted survival and growth of established tumor 
cells. This model of curaxins specifically targeting FACT complex would be able to explain 
the finding of Barone’s study where curaxins accumulate in tumor. However, curaxins do 
not bind to FACT complex as later studies have suggested that curaxins bind to DNA. 
Therefore the curaxins binding should not be affected by the expression level of FACT 
complex. Another possible explanation is the increased metabolism and blood supply of 
tumors. Once curaxins cross the BBB, the tumor cells are able to uptake the curaxins 
given the abundant blood supply. Nevertheless, the ability of curaxins to cross BBB and 
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